Comparison of the effectiveness of interferon in chronic myeloproliferative disorders.
\r\n\tThe present book intends to provide to the reader a comprehensive overview of the state of art in empathy studies, embracing the different theoretical points of view and illustrating the advanced research such as the application of new technologies to promote perspective-taking. The critical aspects and the future directions of the study on empathy will also be presented.
",isbn:"978-1-80356-612-2",printIsbn:"978-1-80356-611-5",pdfIsbn:"978-1-80356-613-9",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,isNomenclature:!1,hash:"4c1042dfe15aa9cea6019524c4cbff38",bookSignature:"Ph.D. Sara Ventura",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11443.jpg",keywords:"Theoretical Model, Skill, Perspective Taking, Training Programs, Practical Implications, Advanced Research, Future Directions, Virtual Reality, Augmented Reality, New Trends, Assistive Technology",numberOfDownloads:21,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"April 1st 2022",dateEndSecondStepPublish:"June 8th 2022",dateEndThirdStepPublish:"August 7th 2022",dateEndFourthStepPublish:"October 26th 2022",dateEndFifthStepPublish:"December 25th 2022",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"2 months",secondStepPassed:!0,areRegistrationsClosed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"Passionate researcher in the application of new technologies to psychological treatments, neuro-rehabilitation, human behavior, and the evolution of the human-computer interaction. In 2017 Dr. Ventura won a competitive grant (Santiago Grisolia) at the University of Valencia at LABPSITEC group, where she was awarded her Ph.D. degree, supervised by Prof. Rosa Baños at the University of Valencia, and co-directed by Prof. Giuseppe Riva of the Catholic University of Milan.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"227763",title:"Ph.D.",name:"Sara",middleName:null,surname:"Ventura",slug:"sara-ventura",fullName:"Sara Ventura",profilePictureURL:"https://mts.intechopen.com/storage/users/227763/images/system/227763.jpg",biography:"Sara Ventura gained a B.Sc in Psychology at the University of Padua (Italy) in 2013 and an M.Sc. in Ergonomic Psychology at the Catholic University of Milan (Italy) in 2015. In 2016, she carried out a postgraduate training at Universidad Nacional Autónoma de Mexico (Mexico) at the Ciberpsychology lab, working on a rehabilitation protocol for people with acquired brain injury through Virtual Reality. In 2020, Sara gained the Ph.D. in Clinical Psychology at University of Valencia (Spain) working with the LabPsitec group and focusing her research on the study of embodiment and empathy with the support of Virtual Reality. Actually, she is working both with Alma Mater Studiorum – University of Bologna (Italy), and the University of Valencia (Spain) on the fields of embodiment, stroke rehabilitation, empathy and patient care. Her research interests mainly focus on the adoption of new technologies, particularly Virtual/Augmented Reality and Artificial Intelligence for the psycho-social wellbeing with clinical and non-clinical populations, the study of human-computer interaction, and the user experience. She is the author of several scientific papers and various presentations at national and international conferences.",institutionString:"University of Valencia",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"University of Valencia",institutionURL:null,country:{name:"Spain"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"21",title:"Psychology",slug:"psychology"}],chapters:[{id:"82719",title:"Empathy as a High-Performance Competency",slug:"empathy-as-a-high-performance-competency",totalDownloads:14,totalCrossrefCites:0,authors:[null]},{id:"82888",title:"From Empathy to the Aggression–Compassion Continuum",slug:"from-empathy-to-the-aggression-compassion-continuum",totalDownloads:7,totalCrossrefCites:0,authors:[{id:"191531",title:"Dr.",name:"Neil E.",surname:"Grunberg",slug:"neil-e.-grunberg",fullName:"Neil E. Grunberg"},{id:"191532",title:"Dr.",name:"Erin S.",surname:"Barry",slug:"erin-s.-barry",fullName:"Erin S. Barry"}]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"455410",firstName:"Dajana",lastName:"Jusic",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/455410/images/20500_n.jpeg",email:"dajana.j@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6494",title:"Behavior Analysis",subtitle:null,isOpenForSubmission:!1,hash:"72a81a7163705b2765f9eb0b21dec70e",slug:"behavior-analysis",bookSignature:"Huei-Tse Hou and Carolyn S. Ryan",coverURL:"https://cdn.intechopen.com/books/images_new/6494.jpg",editedByType:"Edited by",editors:[{id:"96493",title:"Prof.",name:"Huei Tse",surname:"Hou",slug:"huei-tse-hou",fullName:"Huei Tse Hou"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9052",title:"Psychoanalysis",subtitle:"A New Overview",isOpenForSubmission:!1,hash:"69cc7a085f5417038f532cf11edee22f",slug:"psychoanalysis-a-new-overview",bookSignature:"Floriana Irtelli, Barbara Marchesi and Federico Durbano",coverURL:"https://cdn.intechopen.com/books/images_new/9052.jpg",editedByType:"Edited by",editors:[{id:"174641",title:"Dr.",name:"Floriana",surname:"Irtelli",slug:"floriana-irtelli",fullName:"Floriana Irtelli"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10981",title:"Sport Psychology in Sports, Exercise and Physical Activity",subtitle:null,isOpenForSubmission:!1,hash:"5214c44bdc42978449de0751ca364684",slug:"sport-psychology-in-sports-exercise-and-physical-activity",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/10981.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde Dorthea Grindvik",surname:"Nielsen",slug:"hilde-dorthea-grindvik-nielsen",fullName:"Hilde Dorthea Grindvik Nielsen"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10211",title:"The Science of Emotional Intelligence",subtitle:null,isOpenForSubmission:!1,hash:"447fc7884303a10093bc189f4c82dd47",slug:"the-science-of-emotional-intelligence",bookSignature:"Simon George Taukeni",coverURL:"https://cdn.intechopen.com/books/images_new/10211.jpg",editedByType:"Edited by",editors:[{id:"202046",title:"Dr.",name:"Simon George",surname:"Taukeni",slug:"simon-george-taukeni",fullName:"Simon George Taukeni"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7811",title:"Beauty",subtitle:"Cosmetic Science, Cultural Issues and Creative Developments",isOpenForSubmission:!1,hash:"5f6fd59694706550db8dd1082a8e457b",slug:"beauty-cosmetic-science-cultural-issues-and-creative-developments",bookSignature:"Martha Peaslee Levine and Júlia Scherer Santos",coverURL:"https://cdn.intechopen.com/books/images_new/7811.jpg",editedByType:"Edited by",editors:[{id:"186919",title:"Dr.",name:"Martha",surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"14855",title:"Quality Assessments of Seafloor Mapping with Multibeam Echo Sounders",doi:"10.5772/15668",slug:"quality-assessments-of-seafloor-mapping-with-multibeam-echo-sounders",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/14855.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/14855",previewPdfUrl:"/chapter/pdf-preview/14855",totalDownloads:3256,totalViews:71,totalCrossrefCites:0,totalDimensionsCites:0,totalAltmetricsMentions:0,introChapter:null,impactScore:0,impactScorePercentile:27,impactScoreQuartile:2,hasAltmetrics:0,dateSubmitted:"June 14th 2010",dateReviewed:"November 5th 2010",datePrePublished:null,datePublished:"April 26th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/14855",risUrl:"/chapter/ris/14855",book:{id:"95",slug:"applications-and-experiences-of-quality-control"},signatures:"Jan Terje Bjørke and Stein Nilsen",authors:[{id:"21555",title:"Dr.",name:"Jan Terje",middleName:null,surname:"Bjørke",fullName:"Jan Terje Bjørke",slug:"jan-terje-bjorke",email:"jtb@ffi.no",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Norwegian Defence Research Establishment",institutionURL:null,country:{name:"Norway"}}},{id:"22144",title:"Dr.",name:"Stein",middleName:null,surname:"Nilsen",fullName:"Stein Nilsen",slug:"stein-nilsen",email:"sni@ffi.no",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Norwegian Defence Research Establishment",institutionURL:null,country:{name:"Norway"}}}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"95",type:"book",title:"Applications and Experiences of Quality Control",subtitle:null,fullTitle:"Applications and Experiences of Quality Control",slug:"applications-and-experiences-of-quality-control",publishedDate:"April 26th 2011",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",licenceType:"CC BY-NC-SA 3.0",editedByType:"Edited by",isbn:null,printIsbn:"978-953-307-236-4",pdfIsbn:"978-953-51-6008-3",reviewType:"peer-reviewed",numberOfWosCitations:72,isAvailableForWebshopOrdering:!0,editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"806"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"14834",type:"chapter",title:"Quality Indicators for Colonoscopy Procedures",slug:"quality-indicators-for-colonoscopy-procedures",totalDownloads:3503,totalCrossrefCites:0,signatures:"Romain Coriat, Elise Pommaret, Sarah Leblanc and Stanislas Chaussade",reviewType:"peer-reviewed",authors:[{id:"18316",title:"Dr.",name:"Romain",middleName:null,surname:"Coriat",fullName:"Romain Coriat",slug:"romain-coriat"}]},{id:"14835",type:"chapter",title:"The Need for Quality Control in High Dose Rate Brachytherapy",slug:"the-need-for-quality-control-in-high-dose-rate-brachytherapy",totalDownloads:3581,totalCrossrefCites:0,signatures:"Carlos E. deAlmeida",reviewType:"peer-reviewed",authors:[{id:"22025",title:"Dr.",name:"Carlos Eduardo",middleName:null,surname:"De Almeida",fullName:"Carlos Eduardo De Almeida",slug:"carlos-eduardo-de-almeida"}]},{id:"14836",type:"chapter",title:"Applications and Experiences of Quality Control to Surgical and Interventional Procedures",slug:"applications-and-experiences-of-quality-control-to-surgical-and-interventional-procedures",totalDownloads:2665,totalCrossrefCites:2,signatures:"David Biau, Lionel Dessolle and Raphaël Porcher",reviewType:"peer-reviewed",authors:[{id:"22297",title:"Dr.",name:"David J.",middleName:null,surname:"Biau",fullName:"David J. Biau",slug:"david-j.-biau"}]},{id:"14837",type:"chapter",title:"Whole Body Composition by Hologic QDR 4500/A DXA: System Reliability versus User Accuracy and Precision",slug:"whole-body-composition-by-hologic-qdr-4500-a-dxa-system-reliability-versus-user-accuracy-and-precisi",totalDownloads:6978,totalCrossrefCites:3,signatures:"Aldo Scafoglieri, Steven Provyn, Joanne Wallace, Olivia Louis, Jonathan Tresignie, Ivan Bautmans, Johan De Mey and Jan Pieter Clarys",reviewType:"peer-reviewed",authors:[{id:"12647",title:"Dr.",name:"Aldo",middleName:null,surname:"Scafoglieri",fullName:"Aldo Scafoglieri",slug:"aldo-scafoglieri"},{id:"12649",title:"Prof.",name:"Steven",middleName:null,surname:"Provyn",fullName:"Steven Provyn",slug:"steven-provyn"},{id:"12651",title:"Dr.",name:"Jonathan",middleName:null,surname:"Tresignie",fullName:"Jonathan Tresignie",slug:"jonathan-tresignie"},{id:"12652",title:"Dr.",name:"Olivia",middleName:null,surname:"Louis",fullName:"Olivia Louis",slug:"olivia-louis"},{id:"21875",title:"Dr.",name:"Ivan",middleName:null,surname:"Bautmans",fullName:"Ivan Bautmans",slug:"ivan-bautmans"},{id:"21880",title:"Dr.",name:"Joanne",middleName:null,surname:"Wallace",fullName:"Joanne Wallace",slug:"joanne-wallace"},{id:"21882",title:"Dr.",name:"Johan",middleName:null,surname:"De Mey",fullName:"Johan De Mey",slug:"johan-de-mey"},{id:"21883",title:"Prof.",name:"Jan Pieter",middleName:null,surname:"Clarys",fullName:"Jan Pieter Clarys",slug:"jan-pieter-clarys"}]},{id:"14838",type:"chapter",title:"Quality Control in Endoscopy Unit: Safety Considerations for the Patient",slug:"quality-control-in-endoscopy-unit-safety-considerations-for-the-patient",totalDownloads:6249,totalCrossrefCites:0,signatures:"Jean-Francois Rey",reviewType:"peer-reviewed",authors:[{id:"19455",title:"Dr.",name:"Jean-Francois",middleName:null,surname:"Rey",fullName:"Jean-Francois Rey",slug:"jean-francois-rey"}]},{id:"14839",type:"chapter",title:"Development of Urodynamic Standards for Quality Control",slug:"development-of-urodynamic-standards-for-quality-control",totalDownloads:4721,totalCrossrefCites:0,signatures:"Limin Liao and Werner Schaefer",reviewType:"peer-reviewed",authors:[{id:"20116",title:"Dr.",name:"Limin",middleName:null,surname:"Liao",fullName:"Limin Liao",slug:"limin-liao"},{id:"20346",title:"Dr.",name:"Werner",middleName:null,surname:"Schaefer",fullName:"Werner Schaefer",slug:"werner-schaefer"}]},{id:"14840",type:"chapter",title:"Guidelines for Developing Automated Quality Control Procedures for Brain Magnetic Resonance Images Acquired in Multi-Centre Clinical Trials",slug:"guidelines-for-developing-automated-quality-control-procedures-for-brain-magnetic-resonance-images-a",totalDownloads:3343,totalCrossrefCites:1,signatures:"Elias Gedamu",reviewType:"peer-reviewed",authors:[{id:"18017",title:"PhD.",name:"Elias",middleName:null,surname:"Gedamu",fullName:"Elias Gedamu",slug:"elias-gedamu"}]},{id:"14841",type:"chapter",title:"Quality Control in the Early Secretory Pathway Plays Significant Roles in vivo",slug:"quality-control-in-the-early-secretory-pathway-plays-significant-roles-in-vivo",totalDownloads:1981,totalCrossrefCites:0,signatures:"Tomohiko Aoe",reviewType:"peer-reviewed",authors:[{id:"22471",title:"Prof.",name:"Tomohiko",middleName:null,surname:"Aoe",fullName:"Tomohiko Aoe",slug:"tomohiko-aoe"}]},{id:"14842",type:"chapter",title:"Quality Assurance in the Preanalytical Phase",slug:"quality-assurance-in-the-preanalytical-phase",totalDownloads:17066,totalCrossrefCites:1,signatures:"M. Antonia LLopis, Virtudes Alvarez, Cecilia Martínez-Brú, Rubén Gómez, Núria Barba, Mercè Ibarz, Mariano Cortés, Montserrat Ventura and M. Jesús Alsina",reviewType:"peer-reviewed",authors:[{id:"22213",title:"Dr.",name:"Mª Antonia",middleName:null,surname:"LLopis",fullName:"Mª Antonia LLopis",slug:"ma-antonia-llopis"},{id:"22412",title:"Dr.",name:"Virtudes",middleName:null,surname:"Alvarez",fullName:"Virtudes Alvarez",slug:"virtudes-alvarez"},{id:"22413",title:"Dr.",name:"Cecilia",middleName:null,surname:"Martínez-Brú",fullName:"Cecilia Martínez-Brú",slug:"cecilia-martinez-bru"},{id:"22414",title:"Dr.",name:"Rubén",middleName:null,surname:"Gómez",fullName:"Rubén Gómez",slug:"ruben-gomez"},{id:"22415",title:"Prof.",name:"Núria",middleName:null,surname:"Barba",fullName:"Núria Barba",slug:"nuria-barba"},{id:"22416",title:"Prof.",name:"Mercè",middleName:null,surname:"Ibarz",fullName:"Mercè Ibarz",slug:"merce-ibarz"},{id:"22417",title:"Dr.",name:"Mariano",middleName:null,surname:"Cortés",fullName:"Mariano Cortés",slug:"mariano-cortes"},{id:"22418",title:"Dr.",name:"Montserrat",middleName:null,surname:"Ventura",fullName:"Montserrat Ventura",slug:"montserrat-ventura"},{id:"22419",title:"Dr.",name:"Mª Jesús",middleName:null,surname:"Alsina",fullName:"Mª Jesús Alsina",slug:"ma-jesus-alsina"}]},{id:"14843",type:"chapter",title:"The Need for Quality for Better Laboratory Performance, Alexandria University Experience",slug:"the-need-for-quality-for-better-laboratory-performance-alexandria-university-experience",totalDownloads:7025,totalCrossrefCites:0,signatures:"Mohamed Moustafa Rizk, Abla Abou Zeid and Nermine Hossam",reviewType:"peer-reviewed",authors:[{id:"18424",title:"Prof.",name:"Mohamed Moustafa",middleName:"Mohamed",surname:"Rizk",fullName:"Mohamed Moustafa Rizk",slug:"mohamed-moustafa-rizk"},{id:"20021",title:"Prof.",name:"Abla",middleName:null,surname:"Abou Zeid",fullName:"Abla Abou Zeid",slug:"abla-abou-zeid"},{id:"20022",title:"Prof.",name:"Nermine",middleName:null,surname:"Hossam",fullName:"Nermine Hossam",slug:"nermine-hossam"}]},{id:"14844",type:"chapter",title:"Quality Control for the Molecular Diagnosis of Toxoplasmosis",slug:"quality-control-for-the-molecular-diagnosis-of-toxoplasmosis",totalDownloads:2669,totalCrossrefCites:0,signatures:"Emmanuelle Varlet-Marie, Yvon Sterkers and Patrick Bastien",reviewType:"peer-reviewed",authors:[{id:"18927",title:"Prof.",name:"Patrick",middleName:null,surname:"Bastien",fullName:"Patrick Bastien",slug:"patrick-bastien"},{id:"30700",title:"Dr.",name:"Emmanuelle",middleName:null,surname:"Varlet-Marie",fullName:"Emmanuelle Varlet-Marie",slug:"emmanuelle-varlet-marie"},{id:"30701",title:"Dr.",name:"Yvon",middleName:null,surname:"Sterkers",fullName:"Yvon Sterkers",slug:"yvon-sterkers"}]},{id:"14845",type:"chapter",title:"Quality and Safety in PICU and NICU: Scoreboard Control and Care Network",slug:"quality-and-safety-in-picu-and-nicu-scoreboard-control-and-care-network",totalDownloads:4924,totalCrossrefCites:0,signatures:"Fuster-Jorge, P.A., Fernández-Sarabia, J., Delgado-Melián, T., Pérez-Hernández, R., Jiménez-Rivera J.J., Montes de Oca-Afonso M.R., Domenech-Martínez, E. and Sierra-López, A.",reviewType:"peer-reviewed",authors:[{id:"21170",title:"Dr.",name:"Pedro A.",middleName:null,surname:"Fuster Jorge",fullName:"Pedro A. Fuster Jorge",slug:"pedro-a.-fuster-jorge"},{id:"21234",title:"Dr.",name:"Javier",middleName:null,surname:"Fernández Sarabia",fullName:"Javier Fernández Sarabia",slug:"javier-fernandez-sarabia"}]},{id:"14846",type:"chapter",title:"Primer Design to Sequence Analysis - a Pipeline for a Molecular Genetic Diagnostic Laboratory",slug:"primer-design-to-sequence-analysis-a-pipeline-for-a-molecular-genetic-diagnostic-laboratory",totalDownloads:4931,totalCrossrefCites:0,signatures:"Elaine Doherty, Renate Marquis-Nicholson, Jennifer M. Love, Clare Brookes, Debra Prosser and Donald R. Love",reviewType:"peer-reviewed",authors:[{id:"18995",title:"Dr.",name:"Donald R.",middleName:null,surname:"Love",fullName:"Donald R. Love",slug:"donald-r.-love"},{id:"18997",title:"BSc.",name:"Elaine",middleName:null,surname:"Doherty",fullName:"Elaine Doherty",slug:"elaine-doherty"},{id:"18998",title:"Ms.",name:"Jennifer M.",middleName:null,surname:"Love",fullName:"Jennifer M. Love",slug:"jennifer-m.-love"},{id:"18999",title:"Ms.",name:"Debra",middleName:null,surname:"Prosser",fullName:"Debra Prosser",slug:"debra-prosser"}]},{id:"14847",type:"chapter",title:"Innovative Approaches in Quality Management in Clinical Laboratories",slug:"innovative-approaches-in-quality-management-in-clinical-laboratories",totalDownloads:11896,totalCrossrefCites:1,signatures:"Lina Souan, Maher A. Sughayer",reviewType:"peer-reviewed",authors:[{id:"20023",title:"Dr.",name:"Lina",middleName:null,surname:"Souan",fullName:"Lina Souan",slug:"lina-souan"},{id:"23632",title:"Dr.",name:"Maher A.",middleName:null,surname:"Sughayer",fullName:"Maher A. Sughayer",slug:"maher-a.-sughayer"}]},{id:"15831",type:"chapter",title:"Mathematically Fuzzy Approach to Quality Control",slug:"mathematically-fuzzy-approach-to-quality-control",totalDownloads:2604,totalCrossrefCites:0,signatures:"Rostovtsev A.M.",reviewType:"peer-reviewed",authors:[{id:"19840",title:"MSc.",name:"Andrey",middleName:null,surname:"Rostovtsev",fullName:"Andrey Rostovtsev",slug:"andrey-rostovtsev"}]},{id:"14848",type:"chapter",title:"On Some Applications of Nonlinear Differential Equations in Image Processing: Concepts and Electronic Implementation",slug:"on-some-applications-of-nonlinear-differential-equations-in-image-processing-concepts-and-electronic",totalDownloads:2670,totalCrossrefCites:0,signatures:"S. Morfu and P. Marquié",reviewType:"peer-reviewed",authors:[{id:"21473",title:"Dr.",name:"Saverio",middleName:null,surname:"Morfu",fullName:"Saverio Morfu",slug:"saverio-morfu"},{id:"22251",title:"Prof.",name:"Patrick",middleName:null,surname:"Marquie",fullName:"Patrick Marquie",slug:"patrick-marquie"}]},{id:"14849",type:"chapter",title:"Quality Control in Clinical Laboratories",slug:"quality-control-in-clinical-laboratories",totalDownloads:80347,totalCrossrefCites:10,signatures:"Petros Karkalousos and Angelos Evangelopoulos",reviewType:"peer-reviewed",authors:[{id:"21886",title:"Dr.",name:"Petros",middleName:"L",surname:"Karkalousos",fullName:"Petros Karkalousos",slug:"petros-karkalousos"},{id:"24306",title:"Dr.",name:"Angelos",middleName:null,surname:"Evangelopoulos",fullName:"Angelos Evangelopoulos",slug:"angelos-evangelopoulos"}]},{id:"14850",type:"chapter",title:"Water Quality Control from the Perspective of Water Supply System Users’ Safety",slug:"water-quality-control-from-the-perspective-of-water-supply-system-users-safety",totalDownloads:2241,totalCrossrefCites:0,signatures:"Janusz Ryszard Rak and Barbara Tchórzewska-Cieślak",reviewType:"peer-reviewed",authors:[{id:"22265",title:"Dr.",name:"Janusz Ryszard",middleName:null,surname:"Rak",fullName:"Janusz Ryszard Rak",slug:"janusz-ryszard-rak"},{id:"22296",title:"Dr.",name:"Barbara",middleName:null,surname:"Tchorzewska-Cieslak",fullName:"Barbara Tchorzewska-Cieslak",slug:"barbara-tchorzewska-cieslak"}]},{id:"14851",type:"chapter",title:"The Application Research of Intelligent Quality Control Based on Failure Mode and Effects Analysis Knowledge Management",slug:"the-application-research-of-intelligent-quality-control-based-on-failure-mode-and-effects-analysis-k",totalDownloads:3190,totalCrossrefCites:0,signatures:"Zhao Xiuxu",reviewType:"peer-reviewed",authors:[{id:"19311",title:"Prof.",name:"Xiuxu",middleName:null,surname:"Zhao",fullName:"Xiuxu Zhao",slug:"xiuxu-zhao"}]},{id:"14852",type:"chapter",title:"Model Driven Adaptive Quality Control in Service Oriented Architectures",slug:"model-driven-adaptive-quality-control-in-service-oriented-architectures",totalDownloads:2002,totalCrossrefCites:1,signatures:"Tomasz Szydło and Krzysztof Zieliński",reviewType:"peer-reviewed",authors:[{id:"21977",title:"Prof.",name:"Krzysztof",middleName:null,surname:"Zieliński",fullName:"Krzysztof Zieliński",slug:"krzysztof-zielinski"},{id:"22486",title:"MSc.",name:"Tomasz",middleName:null,surname:"Szydło",fullName:"Tomasz Szydło",slug:"tomasz-szydlo"}]},{id:"14853",type:"chapter",title:"Research about New Predictive-Maintenance Methodology using VBA for Marine Engineering Applications",slug:"research-about-new-predictive-maintenance-methodology-using-vba-for-marine-engineering-applications",totalDownloads:2836,totalCrossrefCites:0,signatures:"José A. Orosa, Angel M. Costa and Rafael Santos",reviewType:"peer-reviewed",authors:[{id:"10150",title:"Prof.",name:"José A.",middleName:null,surname:"Orosa",fullName:"José A. Orosa",slug:"jose-a.-orosa"},{id:"23371",title:"Prof.",name:"Angel M.",middleName:null,surname:"Costa",fullName:"Angel M. Costa",slug:"angel-m.-costa"},{id:"136232",title:"Prof.",name:"Rafael",middleName:null,surname:"Santos",fullName:"Rafael Santos",slug:"rafael-santos"}]},{id:"14854",type:"chapter",title:"Development of VBA Based Ship Technical Corrective Management System for Marine Engineers",slug:"development-of-vba-based-ship-technical-corrective-management-system-for-marine-engineers",totalDownloads:3892,totalCrossrefCites:0,signatures:"José A. Orosa, Angel M. Costa and Rafael Santos",reviewType:"peer-reviewed",authors:[{id:"10150",title:"Prof.",name:"José A.",middleName:null,surname:"Orosa",fullName:"José A. Orosa",slug:"jose-a.-orosa"},{id:"23371",title:"Prof.",name:"Angel M.",middleName:null,surname:"Costa",fullName:"Angel M. Costa",slug:"angel-m.-costa"},{id:"136232",title:"Prof.",name:"Rafael",middleName:null,surname:"Santos",fullName:"Rafael Santos",slug:"rafael-santos"}]},{id:"14855",type:"chapter",title:"Quality Assessments of Seafloor Mapping with Multibeam Echo Sounders",slug:"quality-assessments-of-seafloor-mapping-with-multibeam-echo-sounders",totalDownloads:3256,totalCrossrefCites:0,signatures:"Jan Terje Bjørke and Stein Nilsen",reviewType:"peer-reviewed",authors:[{id:"21555",title:"Dr.",name:"Jan Terje",middleName:null,surname:"Bjørke",fullName:"Jan Terje Bjørke",slug:"jan-terje-bjorke"},{id:"22144",title:"Dr.",name:"Stein",middleName:null,surname:"Nilsen",fullName:"Stein Nilsen",slug:"stein-nilsen"}]},{id:"14856",type:"chapter",title:"Electrochemical Methods in Analysis of Biofuels",slug:"electrochemical-methods-in-analysis-of-biofuels",totalDownloads:3656,totalCrossrefCites:0,signatures:"André L. Santos, Regina M. Takeuchi, Paula G. Fenga and Nelson R. Stradiotto",reviewType:"peer-reviewed",authors:[{id:"22070",title:"Dr.",name:"Nelson R.",middleName:null,surname:"Stradiotto",fullName:"Nelson R. Stradiotto",slug:"nelson-r.-stradiotto"},{id:"40729",title:"PhD.",name:"André L.",middleName:null,surname:"Santos",fullName:"André L. Santos",slug:"andre-l.-santos"},{id:"40740",title:"Dr.",name:"Paula G.",middleName:null,surname:"Fenga",fullName:"Paula G. Fenga",slug:"paula-g.-fenga"},{id:"41041",title:"Dr.",name:"Regina M.",middleName:null,surname:"Takeuchi",fullName:"Regina M. Takeuchi",slug:"regina-m.-takeuchi"}]},{id:"14857",type:"chapter",title:"Quality Control Implementation in Manufacturing Companies: Motivating Factors and Challenges",slug:"quality-control-implementation-in-manufacturing-companies-motivating-factors-and-challenges",totalDownloads:78576,totalCrossrefCites:3,signatures:"Hairulliza Mohamad Judi, Ruzzakiah Jenal and Devendran Genasan",reviewType:"peer-reviewed",authors:[{id:"21941",title:"PhD.",name:"Hairulliza",middleName:null,surname:"Mohamad Judi",fullName:"Hairulliza Mohamad Judi",slug:"hairulliza-mohamad-judi"},{id:"26901",title:"PhD.",name:"Ruzzakiah",middleName:null,surname:"Jenal",fullName:"Ruzzakiah Jenal",slug:"ruzzakiah-jenal"},{id:"26902",title:"Mr.",name:"Devendran",middleName:null,surname:"Genasan",fullName:"Devendran Genasan",slug:"devendran-genasan"}]},{id:"14858",type:"chapter",title:"Quality Control Methods Based on Electromagnetic Field-Matter Interactions",slug:"quality-control-methods-based-on-electromagnetic-field-matter-interactions",totalDownloads:2009,totalCrossrefCites:1,signatures:"Ognyan Ivanov and Mariana Kuneva",reviewType:"peer-reviewed",authors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",fullName:"Ognyan Ivanov",slug:"ognyan-ivanov"},{id:"22236",title:"Dr.",name:"Mariana",middleName:null,surname:"Kuneva",fullName:"Mariana Kuneva",slug:"mariana-kuneva"}]},{id:"14859",type:"chapter",title:"Process Monitoring of Polymer Systems by using Near-Infrared Spectroscopy",slug:"process-monitoring-of-polymer-systems-by-using-near-infrared-spectroscopy",totalDownloads:5238,totalCrossrefCites:2,signatures:"Wei Li",reviewType:"peer-reviewed",authors:[{id:"19968",title:"Dr.",name:"Wei",middleName:null,surname:"Li",fullName:"Wei Li",slug:"wei-li"}]},{id:"14860",type:"chapter",title:"Digital Image Processing for Quality Control on Injection Molding Products",slug:"digital-image-processing-for-quality-control-on-injection-molding-products",totalDownloads:5104,totalCrossrefCites:0,signatures:"Marco Sasso, Massimo Natalini and Dario Amodio",reviewType:"peer-reviewed",authors:[{id:"21568",title:"Dr.",name:"Marco",middleName:null,surname:"Sasso",fullName:"Marco Sasso",slug:"marco-sasso"},{id:"22467",title:"Prof.",name:"Massimo",middleName:null,surname:"Natalini",fullName:"Massimo Natalini",slug:"massimo-natalini"},{id:"22468",title:"Prof.",name:"Dario",middleName:null,surname:"Amodio",fullName:"Dario Amodio",slug:"dario-amodio"}]},{id:"14861",type:"chapter",title:"Power Quality Control in Wind/Fuel Cell/Battery/Hydrogen Electrolyzer Hybrid Micro-grid Power System",slug:"power-quality-control-in-wind-fuel-cell-battery-hydrogen-electrolyzer-hybrid-micro-grid-power-system",totalDownloads:4453,totalCrossrefCites:12,signatures:"Xiangjun Li, Dong Hui, Xiaokang Lai and Tao Yan",reviewType:"peer-reviewed",authors:[{id:"18171",title:"Dr.",name:"Xiangjun",middleName:null,surname:"Li",fullName:"Xiangjun Li",slug:"xiangjun-li"},{id:"136234",title:"Prof.",name:"Dong",middleName:null,surname:"Hui",fullName:"Dong Hui",slug:"dong-hui"},{id:"136235",title:"Prof.",name:"Xiaokang",middleName:null,surname:"Lai",fullName:"Xiaokang Lai",slug:"xiaokang-lai"},{id:"136237",title:"Prof.",name:"Tao",middleName:null,surname:"Yan",fullName:"Tao Yan",slug:"tao-yan"}]},{id:"14862",type:"chapter",title:"A Discussion on Current Quality-Control Practices in Mineral Exploration",slug:"a-discussion-on-current-quality-control-practices-in-mineral-exploration",totalDownloads:10220,totalCrossrefCites:0,signatures:"Armando Simón Méndez",reviewType:"peer-reviewed",authors:[{id:"17938",title:"Dr.",name:"Armando Simón",middleName:"A.",surname:"Méndez",fullName:"Armando Simón Méndez",slug:"armando-simon-mendez"}]},{id:"14863",type:"chapter",title:"Sampling Errors and Control of Assay Data Quality in Exploration and Mining Geology",slug:"sampling-errors-and-control-of-assay-data-quality-in-exploration-and-mining-geology",totalDownloads:15359,totalCrossrefCites:3,signatures:"Marat Abzalov",reviewType:"peer-reviewed",authors:[{id:"19362",title:"Dr.",name:"Marat",middleName:null,surname:"Abzalov",fullName:"Marat Abzalov",slug:"marat-abzalov"}]},{id:"14864",type:"chapter",title:"Adaptive Calibration and Quality Control of Smart Sensors",slug:"adaptive-calibration-and-quality-control-of-smart-sensors",totalDownloads:3391,totalCrossrefCites:1,signatures:"Matej Možek, Danilo Vrtačnik, Drago Resnik, Borut Pečar and Slavko Amon",reviewType:"peer-reviewed",authors:[{id:"18182",title:"Dr.",name:"Matej",middleName:null,surname:"Možek",fullName:"Matej Možek",slug:"matej-mozek"},{id:"22398",title:"Dr.",name:"Danilo",middleName:null,surname:"Vrtačnik",fullName:"Danilo Vrtačnik",slug:"danilo-vrtacnik"},{id:"22399",title:"Dr.",name:"Drago",middleName:null,surname:"Resnik",fullName:"Drago Resnik",slug:"drago-resnik"},{id:"22400",title:"Dr.",name:"Borut",middleName:null,surname:"Pečar",fullName:"Borut Pečar",slug:"borut-pecar"},{id:"22401",title:"Dr.",name:"Slavko",middleName:null,surname:"Amon",fullName:"Slavko Amon",slug:"slavko-amon"}]},{id:"14865",type:"chapter",title:"Hyperspectral Imaging for Raw Material Sorting and Processed Product Quality Control",slug:"hyperspectral-imaging-for-raw-material-sorting-and-processed-product-quality-control",totalDownloads:3822,totalCrossrefCites:1,signatures:"Pilar-Beatriz García-Allende, Olga M. Conde and José Miguel López-Higuera",reviewType:"peer-reviewed",authors:[{id:"21782",title:"Dr.",name:"Pilar-Beatriz",middleName:null,surname:"García-Allende",fullName:"Pilar-Beatriz García-Allende",slug:"pilar-beatriz-garcia-allende"},{id:"21787",title:"Prof.",name:"José Miguel",middleName:null,surname:"López-Higuera",fullName:"José Miguel López-Higuera",slug:"jose-miguel-lopez-higuera"},{id:"22456",title:"Dr.",name:"Olga M.",middleName:null,surname:"Conde",fullName:"Olga M. Conde",slug:"olga-m.-conde"}]},{id:"14866",type:"chapter",title:"Quality Control of the Microlenses Array",slug:"quality-control-of-the-microlenses-array",totalDownloads:2223,totalCrossrefCites:0,signatures:"Rafał Kasztelanic",reviewType:"peer-reviewed",authors:[{id:"19562",title:"Dr.",name:"Rafał",middleName:null,surname:"Kasztelanic",fullName:"Rafał Kasztelanic",slug:"rafal-kasztelanic"}]}]},relatedBooks:[{type:"book",id:"632",title:"Wide Spectra of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"9f7ce64f86daee44a8c5604e8924de1c",slug:"wide-spectra-of-quality-control",bookSignature:"Isin Akyar",coverURL:"https://cdn.intechopen.com/books/images_new/632.jpg",editedByType:"Edited by",editors:[{id:"36323",title:"Dr.",name:"Isin",surname:"Akyar",slug:"isin-akyar",fullName:"Isin Akyar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"23726",title:"Analytical Method Validation",slug:"analytical-method-validation",signatures:"Pedro Lopez Garcia, Ernesto Buffoni, Fabio Pereira Gomes and Jose Luis Vilchez Quero",authors:[{id:"42129",title:"Dr.",name:"Pedro",middleName:null,surname:"López García",fullName:"Pedro López García",slug:"pedro-lopez-garcia"},{id:"54461",title:"MSc",name:"Fabio",middleName:null,surname:"Pereira Gomes",fullName:"Fabio Pereira Gomes",slug:"fabio-pereira-gomes"},{id:"54462",title:"MSc",name:"Ernesto",middleName:null,surname:"Buffoni",fullName:"Ernesto Buffoni",slug:"ernesto-buffoni"},{id:"87969",title:"Prof.",name:"Jose Luis",middleName:null,surname:"Vilchez Quero",fullName:"Jose Luis Vilchez Quero",slug:"jose-luis-vilchez-quero"}]},{id:"23727",title:"General Introduction to Design of Experiments (DOE)",slug:"general-introduction-to-design-of-experiments-doe-",signatures:"Ahmed Badr Eldin",authors:[{id:"47874",title:"Dr.",name:"Ahmed",middleName:null,surname:"Badr Eldin",fullName:"Ahmed Badr Eldin",slug:"ahmed-badr-eldin"}]},{id:"23728",title:"Good Clinical Laboratory Practice (GCLP) for Molecular Based Tests Used in Diagnostic Laboratories",slug:"good-clinical-laboratory-practice-gclp-for-molecular-based-tests-used-in-diagnostic-laboratories",signatures:"Raquel V. Viana and Carole L. Wallis",authors:[{id:"54659",title:"Dr.",name:"Carole",middleName:null,surname:"Wallis",fullName:"Carole Wallis",slug:"carole-wallis"},{id:"60112",title:"Ms",name:"Raquel",middleName:null,surname:"Viana",fullName:"Raquel Viana",slug:"raquel-viana"}]},{id:"23729",title:"Quality of the Trace Element Analysis: Sample Preparation Steps",slug:"quality-of-the-trace-element-analysis-sample-preparation-steps",signatures:"Maja Welna, Anna Szymczycha-Madeja and Pawel Pohl",authors:[{id:"42597",title:"Dr.",name:"Pawel",middleName:null,surname:"Pohl",fullName:"Pawel Pohl",slug:"pawel-pohl"},{id:"53899",title:"Dr.",name:"Maja",middleName:null,surname:"Welna",fullName:"Maja Welna",slug:"maja-welna"},{id:"53900",title:"Dr.",name:"Anna",middleName:null,surname:"Szymczycha-Madeja",fullName:"Anna Szymczycha-Madeja",slug:"anna-szymczycha-madeja"}]},{id:"23730",title:"Aspects of Quality and Project Management in Analyses of Large Scale Sequencing Data",slug:"aspects-of-quality-and-project-management-in-analyses-of-large-scale-sequencing-data",signatures:"von Reumont Björn M, Meid Sandra and Misof Bernhard",authors:[{id:"55355",title:"Dr.",name:"Björn M",middleName:null,surname:"Von Reumont",fullName:"Björn M Von Reumont",slug:"bjorn-m-von-reumont"},{id:"102363",title:"Prof.",name:"Bernhard",middleName:null,surname:"Misof",fullName:"Bernhard Misof",slug:"bernhard-misof"},{id:"102364",title:"MSc.",name:"Sandra",middleName:"A",surname:"Meid",fullName:"Sandra Meid",slug:"sandra-meid"}]},{id:"23731",title:"Gene Markers Representing Stem Cells and Cancer Cells for Quality Control",slug:"gene-markers-representing-stem-cells-and-cancer-cells-for-quality-control",signatures:"Shihori Tanabe",authors:[{id:"48635",title:"Dr.",name:"Shihori",middleName:null,surname:"Tanabe",fullName:"Shihori Tanabe",slug:"shihori-tanabe"}]},{id:"23732",title:"Study of Degradation Products and Degradation Pathways of ECD and Its Drug Product, ECD Kit",slug:"study-of-degradation-products-and-degradation-pathways-of-ecd-and-its-drug-product-ecd-kit",signatures:"Kung-Tien Liu, Yu-Yung Lin, Yi-Chih Hsia, Jian-Hua Zhao, Chang-Yung Su, Shang-Yu Shen, Lee-Chung Men and Lie-Hang Shen",authors:[{id:"36122",title:"PhD.",name:"Kung-Tien",middleName:null,surname:"Liu",fullName:"Kung-Tien Liu",slug:"kung-tien-liu"},{id:"52883",title:"Mr",name:"Yu-Yung",middleName:null,surname:"Lin",fullName:"Yu-Yung Lin",slug:"yu-yung-lin"},{id:"52884",title:"Mr",name:"Shang-Yu",middleName:null,surname:"Shen",fullName:"Shang-Yu Shen",slug:"shang-yu-shen"},{id:"52885",title:"Mrs.",name:"Yi-Chih",middleName:null,surname:"Hsia",fullName:"Yi-Chih Hsia",slug:"yi-chih-hsia"},{id:"52886",title:"Dr.",name:"Lee-Chung",middleName:null,surname:"Men",fullName:"Lee-Chung Men",slug:"lee-chung-men"},{id:"52887",title:"Dr.",name:"Lie-Hang",middleName:null,surname:"Shen",fullName:"Lie-Hang Shen",slug:"lie-hang-shen"},{id:"90774",title:"Dr.",name:"Jian-Hua",middleName:null,surname:"Zhao",fullName:"Jian-Hua Zhao",slug:"jian-hua-zhao"},{id:"90775",title:"Mr.",name:"Chang-Yung",middleName:null,surname:"Su",fullName:"Chang-Yung Su",slug:"chang-yung-su"}]},{id:"23733",title:"Analog and Digital Systems of Imaging in Roentgenodiagnostics",slug:"analog-and-digital-systems-of-imaging-in-roentgenodiagnostics",signatures:"Dominika Oborska-Kumaszynska",authors:[{id:"36485",title:"PhD.",name:"Dominika",middleName:"Izabela",surname:"Oborska-Kumaszynska",fullName:"Dominika Oborska-Kumaszynska",slug:"dominika-oborska-kumaszynska"}]},{id:"23734",title:"Quality Assessment of Solid Pharmaceuticals and Intravenous Fluid Manufacturing in Sub-Saharan Africa",slug:"quality-assessment-of-solid-pharmaceuticals-and-intravenous-fluid-manufacturing-in-sub-saharan-afric",signatures:"Adedibu C. Tella, Musa O. Salawu, Lyabo M. Phillips, Ojeyemi M. Olabemiwo and George O. Adediran",authors:[{id:"36184",title:"Dr.",name:"Adedibu",middleName:"Clement",surname:"Tella",fullName:"Adedibu Tella",slug:"adedibu-tella"},{id:"58422",title:"Mr.",name:"Musa",middleName:null,surname:"Salawu",fullName:"Musa Salawu",slug:"musa-salawu"},{id:"96556",title:"Dr.",name:"Iyabo",middleName:null,surname:"Phillips",fullName:"Iyabo Phillips",slug:"iyabo-phillips"},{id:"96562",title:"Dr.",name:"Ojeyemi",middleName:null,surname:"Olabemiwo",fullName:"Ojeyemi Olabemiwo",slug:"ojeyemi-olabemiwo"},{id:"96570",title:"Prof.",name:"George",middleName:null,surname:"Adediran",fullName:"George Adediran",slug:"george-adediran"}]},{id:"23735",title:"Need for Quality Assurance Program of Donor Screening Tests",slug:"need-for-quality-assurance-program-of-donor-screening-tests",signatures:"Young Joo Cha",authors:[{id:"42386",title:"Prof.",name:"Young Joo",middleName:null,surname:"Cha",fullName:"Young Joo Cha",slug:"young-joo-cha"}]},{id:"23736",title:"Quality Control in Pharmaceuticals: Residual Solvents Testing and Analysis",slug:"quality-control-in-pharmaceuticals-residual-solvents-testing-and-analysis",signatures:"Changqin Hu and Ying Liu",authors:[{id:"50302",title:"Prof.",name:"Changqin",middleName:null,surname:"Hu",fullName:"Changqin Hu",slug:"changqin-hu"},{id:"51182",title:"Dr.",name:"Ying",middleName:null,surname:"Liu",fullName:"Ying Liu",slug:"ying-liu"}]},{id:"23737",title:"The Application of the Potentiometric Stripping Analysis to Determine Traces of M(II) Metals (Cu, Zn, Pb and Cd) in Bioinorganic and Similar Materials",slug:"the-application-of-the-potentiometric-stripping-analysis-to-determine-traces-of-m-ii-metals-cu-zn-pb",signatures:"Biljana Kaličanin and Ružica Nikolić",authors:[{id:"56318",title:"Prof.",name:"Biljana",middleName:"Miroslav",surname:"Kalicanin",fullName:"Biljana Kalicanin",slug:"biljana-kalicanin"},{id:"58647",title:"Prof.",name:"Ruzica",middleName:null,surname:"Nikolic",fullName:"Ruzica Nikolic",slug:"ruzica-nikolic"}]},{id:"23738",title:"Near Infra Red Spectroscopy",slug:"near-infra-red-spectroscopy",signatures:"Ahmed Badr Eldin",authors:[{id:"47874",title:"Dr.",name:"Ahmed",middleName:null,surname:"Badr Eldin",fullName:"Ahmed Badr Eldin",slug:"ahmed-badr-eldin"}]},{id:"23739",title:"Quality Control in Hospital Bone Banking",slug:"quality-control-in-hospital-bone-banking",signatures:"Eline Zwitser and Barend van Royen",authors:[{id:"50928",title:"Prof.",name:"Barend J.",middleName:null,surname:"Van Royen",fullName:"Barend J. Van Royen",slug:"barend-j.-van-royen"},{id:"90837",title:"MSc.",name:"Eline W.",middleName:null,surname:"Zwitser",fullName:"Eline W. Zwitser",slug:"eline-w.-zwitser"}]},{id:"23740",title:"Future Applications of Electronic-Nose Technologies in Healthcare and Biomedicine",slug:"future-applications-of-electronic-nose-technologies-in-healthcare-and-biomedicine",signatures:"Alphus Dan Wilson",authors:[{id:"40680",title:"Dr.",name:"Alphus",middleName:"Dan",surname:"Wilson",fullName:"Alphus Wilson",slug:"alphus-wilson"}]},{id:"23741",title:"Quality Assurance and Quality Control of Equipment in Diagnostic Radiology Practice-The Ghanaian Experience",slug:"quality-assurance-and-quality-control-of-equipment-in-diagnostic-radiology-practice-the-ghanaian-exp",signatures:"Stephen Inkoom, Cyril Schandorf, Geoffrey Emi-Reynolds and John Justice Fletcher",authors:[{id:"48333",title:"Mr",name:"Stephen",middleName:null,surname:"Inkoom",fullName:"Stephen Inkoom",slug:"stephen-inkoom"},{id:"55912",title:"Prof.",name:"Cyril",middleName:null,surname:"Schandorf",fullName:"Cyril Schandorf",slug:"cyril-schandorf"},{id:"55913",title:"Prof.",name:"Geoffrey",middleName:null,surname:"Emi-Reynolds",fullName:"Geoffrey Emi-Reynolds",slug:"geoffrey-emi-reynolds"},{id:"55914",title:"Prof.",name:"John",middleName:null,surname:"Fletcher",fullName:"John Fletcher",slug:"john-fletcher"}]},{id:"23742",title:"Pressure-Sensitive Adhesives for Medical Applications",slug:"pressure-sensitive-adhesives-for-medical-applications",signatures:"Zbigniew Czech and Agnieszka Kowalczyk",authors:[{id:"53922",title:"Prof.",name:"Zbigniew",middleName:null,surname:"Czech",fullName:"Zbigniew Czech",slug:"zbigniew-czech"},{id:"94549",title:"Dr.",name:"Agnieszka",middleName:null,surname:"Kowalczyk",fullName:"Agnieszka Kowalczyk",slug:"agnieszka-kowalczyk"},{id:"94550",title:"Dr.",name:"Jolanta",middleName:null,surname:"Swiderska",fullName:"Jolanta Swiderska",slug:"jolanta-swiderska"}]},{id:"23743",title:"The Role of Empirical Rheology in Flour Quality Control",slug:"the-role-of-empirical-rheology-in-flour-quality-control",signatures:"Tamara Dapčević Hadnađev, Milica Pojić, Miroslav Hadnađev and Aleksandra Torbica",authors:[{id:"55755",title:"MSc",name:"Tamara",middleName:null,surname:"Dapčević Hadnađev",fullName:"Tamara Dapčević Hadnađev",slug:"tamara-dapcevic-hadnadjev"},{id:"55801",title:"Dr.",name:"Milica",middleName:null,surname:"Pojić",fullName:"Milica Pojić",slug:"milica-pojic"},{id:"55802",title:"MSc.",name:"Miroslav",middleName:null,surname:"Hadnađev",fullName:"Miroslav Hadnađev",slug:"miroslav-hadnadjev"},{id:"55803",title:"Dr.",name:"Aleksandra",middleName:null,surname:"Torbica",fullName:"Aleksandra Torbica",slug:"aleksandra-torbica"}]},{id:"23744",title:"Sensory Analysis in Quality Control: The Gin as an Example",slug:"sensory-analysis-in-quality-control-the-gin-as-an-example",signatures:"Montserrat Riu Aumatell",authors:[{id:"43906",title:"Dr.",name:"Montserrat",middleName:null,surname:"Riu-Aumatell",fullName:"Montserrat Riu-Aumatell",slug:"montserrat-riu-aumatell"}]},{id:"23745",title:"Spectral Imaging as a Tool in Food Research and Quality Monitoring of Food Production",slug:"spectral-imaging-as-a-tool-in-food-research-and-quality-monitoring-of-food-production",signatures:"Stina Frosch, Bjørn Skovlund Dissing, Jens Adler-Nissen and Michael Engelbrecht Nielsen",authors:[{id:"55298",title:"Dr.",name:"Stina",middleName:null,surname:"Frosch",fullName:"Stina Frosch",slug:"stina-frosch"},{id:"55301",title:"Dr.",name:"Michael",middleName:null,surname:"Engelbrecth Nielsen",fullName:"Michael Engelbrecth Nielsen",slug:"michael-engelbrecth-nielsen"},{id:"55302",title:"Prof.",name:"Jens",middleName:null,surname:"Adler-Nissen",fullName:"Jens Adler-Nissen",slug:"jens-adler-nissen"},{id:"118120",title:"MSc.",name:"Bjørn Skovlund",middleName:null,surname:"Dissing",fullName:"Bjørn Skovlund Dissing",slug:"bjorn-skovlund-dissing"}]},{id:"23746",title:"Mass Rearing and Quality Control Parameters for Tephritid Fruit Flies of Economic Importance in Africa",slug:"mass-rearing-and-quality-control-parameters-for-tephritid-fruit-flies-of-economic-importance-in-afri",signatures:"Sunday Ekesi and Samira A. Mohamed",authors:[{id:"42713",title:"Dr.",name:"Sunday",middleName:null,surname:"Ekesi",fullName:"Sunday Ekesi",slug:"sunday-ekesi"},{id:"53233",title:"Dr.",name:"Samira A.",middleName:null,surname:"Mohamed",fullName:"Samira A. Mohamed",slug:"samira-a.-mohamed"}]},{id:"23747",title:"Quality Control of Baculoviral Bioinsecticide Production",slug:"quality-control-of-baculoviral-bioinsecticide-production",signatures:"Solange Ana Belén Miele, Mariano Nicolás Belaich and Pablo Daniel Ghiringhelli",authors:[{id:"52118",title:"Dr.",name:"Pablo Daniel",middleName:null,surname:"Ghiringhelli",fullName:"Pablo Daniel Ghiringhelli",slug:"pablo-daniel-ghiringhelli"},{id:"54727",title:"Mrs.",name:"Solange Ana Belen",middleName:null,surname:"Miele",fullName:"Solange Ana Belen Miele",slug:"solange-ana-belen-miele"},{id:"54728",title:"Dr.",name:"Mariano Nicolas",middleName:null,surname:"Belaich",fullName:"Mariano Nicolas Belaich",slug:"mariano-nicolas-belaich"}]},{id:"23748",title:"Quality Control and Characterization of Scintillating Crystals for High Energy Physics and Medical Applications",slug:"quality-control-and-characterization-of-scintillating-crystals-for-high-energy-physics-and-medical-a",signatures:"Daniele Rinaldi, Michel Lebeau, Nicola Paone, Lorenzo Scalise and Paolo Pietroni",authors:[{id:"49866",title:"Ph.D.",name:"Lorenzo",middleName:null,surname:"Scalise",fullName:"Lorenzo Scalise",slug:"lorenzo-scalise"},{id:"54920",title:"Prof.",name:"Daniele",middleName:null,surname:"Rinaldi",fullName:"Daniele Rinaldi",slug:"daniele-rinaldi"},{id:"59026",title:"Dr.",name:"Michel",middleName:null,surname:"Lebeau",fullName:"Michel Lebeau",slug:"michel-lebeau"},{id:"59027",title:"Prof.",name:"Nicola",middleName:null,surname:"Paone",fullName:"Nicola Paone",slug:"nicola-paone"},{id:"78731",title:"Dr.",name:"Paolo",middleName:null,surname:"Pietroni",fullName:"Paolo Pietroni",slug:"paolo-pietroni"}]},{id:"23749",title:"Effect of Last Generation Additives on the Concrete Durability",slug:"effect-of-last-generation-additives-on-the-concrete-durability",signatures:"Ana M. Carvajal, M. Soledad Gómez, Pablo Maturana and Raul Molina",authors:[{id:"42072",title:"Prof.",name:"Ana",middleName:"MarÃa",surname:"Carvajal",fullName:"Ana Carvajal",slug:"ana-carvajal"},{id:"42100",title:"Prof.",name:"Pablo",middleName:null,surname:"Maturana",fullName:"Pablo Maturana",slug:"pablo-maturana"},{id:"84065",title:"Prof.",name:"Soledad",middleName:null,surname:"Gomez",fullName:"Soledad Gomez",slug:"soledad-gomez"},{id:"84067",title:"Mr.",name:"Raul",middleName:null,surname:"Molina",fullName:"Raul Molina",slug:"raul-molina"}]},{id:"23750",title:"A Convenient and Inexpensive Quality Control Method for Examining the Accuracy of Conjugate Cam Profiles",slug:"a-convenient-and-inexpensive-quality-control-method-for-examining-the-accuracy-of-conjugate-cam-prof",signatures:"Wen-Tung Chang and Long-Iong Wu",authors:[{id:"43114",title:"Prof.",name:"Wen-Tung",middleName:null,surname:"Chang",fullName:"Wen-Tung Chang",slug:"wen-tung-chang"},{id:"51808",title:"Prof.",name:"Long-Iong",middleName:null,surname:"Wu",fullName:"Long-Iong Wu",slug:"long-iong-wu"}]},{id:"23751",title:"Material Characterization and Failure Analysis for Microelectronics Assembly Processes",slug:"material-characterization-and-failure-analysis-for-microelectronics-assembly-processes",signatures:"Chien-Yi Huang, Ming-Shu Li, Shan-Yu Huang, Cheng-I Chang and Min-Hui Huang",authors:[{id:"52412",title:"Dr.",name:"Ming-Shu",middleName:null,surname:"Li",fullName:"Ming-Shu Li",slug:"ming-shu-li"},{id:"52426",title:"Prof.",name:"Chien-Yi",middleName:"Jay",surname:"Huang",fullName:"Chien-Yi Huang",slug:"chien-yi-huang"},{id:"98841",title:"MSc.",name:"Cheng-I",middleName:null,surname:"Chang",fullName:"Cheng-I Chang",slug:"cheng-i-chang"},{id:"98978",title:"BSc.",name:"Min Hui",middleName:null,surname:"Huang",fullName:"Min Hui Huang",slug:"min-hui-huang"},{id:"99353",title:"MSc.",name:"Shan-Yu",middleName:null,surname:"Huang",fullName:"Shan-Yu Huang",slug:"shan-yu-huang"}]}]}],publishedBooks:[{type:"book",id:"3074",title:"Practical Concepts of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"3bb079fbda0a27f91cd90dcbd0cc3a6b",slug:"practical-concepts-of-quality-control",bookSignature:"Mohammad Saber Fallah Nezhad",coverURL:"https://cdn.intechopen.com/books/images_new/3074.jpg",editedByType:"Edited by",editors:[{id:"150393",title:"Dr.",name:"Mohammad Saber Fallah",surname:"Nezhad",slug:"mohammad-saber-fallah-nezhad",fullName:"Mohammad Saber Fallah Nezhad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8623",title:"Maintenance Management",subtitle:null,isOpenForSubmission:!1,hash:"91cc93ad76fdd6709b8c50c6ba7e4e0c",slug:"maintenance-management",bookSignature:"Fausto Pedro García Márquez and Mayorkinos Papaelias",coverURL:"https://cdn.intechopen.com/books/images_new/8623.jpg",editedByType:"Edited by",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9925",title:"Quality Control",subtitle:"Intelligent Manufacturing, Robust Design and Charts",isOpenForSubmission:!1,hash:"865332c5f031b481c1359793edc79fe5",slug:"quality-control-intelligent-manufacturing-robust-design-and-charts",bookSignature:"Pengzhong Li, Paulo António Rodrigues Pereira and Helena Navas",coverURL:"https://cdn.intechopen.com/books/images_new/9925.jpg",editedByType:"Edited by",editors:[{id:"19636",title:"Prof.",name:"Pengzhong",surname:"Li",slug:"pengzhong-li",fullName:"Pengzhong Li"}],equalEditorOne:{id:"178637",title:"Dr.",name:"Paulo",surname:"Pereira",slug:"paulo-pereira",fullName:"Paulo Pereira"},equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",editedByType:"Edited by",editors:[{id:"22230",title:"Prof.",name:"Ognyan",surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"632",title:"Wide Spectra of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"9f7ce64f86daee44a8c5604e8924de1c",slug:"wide-spectra-of-quality-control",bookSignature:"Isin Akyar",coverURL:"https://cdn.intechopen.com/books/images_new/632.jpg",editedByType:"Edited by",editors:[{id:"36323",title:"Dr.",name:"Isin",surname:"Akyar",slug:"isin-akyar",fullName:"Isin Akyar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",editedByType:"Edited by",editors:[{id:"22230",title:"Prof.",name:"Ognyan",surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"81569",title:"Impact of Interferon Alpha/Beta in the Management of Chronic Myeloproliferative Disorders",doi:"10.5772/intechopen.104501",slug:"impact-of-interferon-alpha-beta-in-the-management-of-chronic-myeloproliferative-disorders",body:'Chronic myeloproliferative disorders are a group of clonal diseases of the stem cell. It is a group of several diseases with some common features. They derive from a multipotential hematopoietic stem cell. A clone of neoplastic cells in all these neoplams is characterized by a lower proliferative activity than that of acute myeloproliferative diseases. In each of these diseases, leukocytosis, thrombocythemia, and polyglobulia may appear at some stage, depending on the diagnosis [1, 2].
The research on interferon has been going on since the 1950s [3]. Then, the attention was paid to its influence on the immune system. It has been noted that it can exert an antiproliferative effect by stimulating cells of the immune system [4]. In 1987, a publication by Ludwig et al. was published, which reported the effectiveness of interferon alpha in the treatment of chronic myeloproliferative disorders [5].
More and more new studies have been showing the effectiveness of interferon alpha in reducing the number of platelets, reducing the need for phlebotomies in patients with polycythemia vera and also in reducing the number of leukocytes. Moreover, interferon reduced the symptoms of myeloproliferative disorders such as redness and itching of the skin. Additionally, it turned out to be effective in reducing the size of the spleen.
Further studies on the assessment of remission using molecular-level response assessments indicate that the interferon action in chronic myeloproliferation diseases targets cells from the mutant clone with no effect on normal bone marrow cells [6].
Over the years, interferon alpha-2a and interferon alpha-2b have been introduced into the treatment of chronic myeloproliferation, followed by their pegylated forms. The introduction of pegylated forms allowed for a reduction in the number of side effects and less frequent administration of the drug to patients. In recent years, monopegylated interferon alpha-2b has been used to further increase the interval between drug administrations while maintaining its antiproliferative efficacy.
The exact mechanism of action of interferon alpha in the treatment of chronic myeloproliferative disease is still not fully understood, but it has an impact on JAK2 (Janus Kinase) signal transducers and activates the STAT signal pathway (Janus Kinase/SignalTransducer and Activator of Transcription).
Interferon alpha binds to IFNAR1 and IFNAR2c, which are type I interferon receptors. Interferon alpha has an impact on JAK2(Janus Kinase) signal transducers and activates the STAT signal pathway. The disturbances in this signaling pathway are observed in chronic myeloproliferative disorders [7].
Interferon inhibits the JAK-STAT signaling pathway by directly inhibiting the action of thrombopoietin in this pathway [8].
So far, three driver mutations have been described in the course of chronic myeloproliferative diseases that affect the functioning of the JAK-STAT pathway.
JAK2 kinase and JAK1, JAK3, and TYK2 kinases belong to the family of non-receptor tyrosine kinases. They are involved in the intracellular signal transduction of the JAK-STAT pathway. It is a system of intracellular proteins used by growth factors and cytokines to express genes that regulate cell activation, proliferation, and differentiation. The mechanism of JAK activation is based on the autophosphorylation of tyrosine residues that occurs after ligand binds to the receptor. JAK2 kinase transmits signals from the hematopoietic cytokine receptors of the myeloid lineage (erythropoietin, granulocyte-colony stimulating factor thrombopoietin, and lymphoid lineage [9].
A somatic G/T point mutation in exon 14 of the JAK2 kinase gene converts valine to phenylalanine at position 617 (V617F) in the JAK2 pseudokinase domain, which allows constitutive, ligand-independent activation of the receptor to trigger a proliferative signal [10].
Mutation of the MPL gene, which encodes the receptor for thrombopoietin, increases the sensitivity of magekaryocytes to the action of thrombopoietin, which stimulates their proliferation [11].
Malfunction of calreticulin as a result of mutation of the CARL gene leads to the activation of the MPL-JAK/STAT signaling pathway, which is independent of the ligand, as calreticulin is responsible, for the proper formation of the MPL receptor. Consequently, there is a clonal proliferation of hematopoietic stem cells [12].
Below, we provide an overview of some clinical studies on the efficacy of interferon in chronic myeloproliferative disorders.
Polycythemia vera (PV) is characterized by an increase in the number of erythrocytes in the peripheral blood.
Polycythemia vera is caused by a clonal mutation in the multipotential hematopoietic stem cell of the bone marrow. The mutation leads to an uncontrolled proliferation of the mutated cell clone, independent of erythropoietin and other regulatory factors. As the mutation takes place at an early stage of hematopoiesis, an increase of the number of erythrocytes as well as of leukocytes and platelets is observed in the peripheral blood. The cause of proliferation in PV independent from external factors is a mutation in the Janus 2 (JAK2) tyrosine kinase gene. The V617F point mutation in the JAK2 gene is responsible for about 96% mutation, and in the remaining cases the mutation arises in exon 12. Both mutations lead to constitutive activation of the JAK-STAT signaling pathway [13].
As a result of the uncontrolled proliferation, blood viscosity increases, which generates symptoms such as headaches and dizziness, visual disturbances, or erythromelalgia. As the number of all hematopoietic cells, including the granulocytes ones, increases, the difficult to control symptoms of their hyperdegranulation may appear, among which gastric ulcer or skin itching is often observed. During the disease progression, the spleen and liver become enlarged.
The most common complication of the disease is episodes of thrombosis, especially arterial one. During the course of the disease, it can also evolve into myelofibrosis or acute myeloid leukemia.
The treatment of PV is aimed at preventing thromboembolic complications, relieving the general symptoms, the appearance of hepatosplenomegaly as well as preventing its progression.
Each patient should receive an antiplatelet drug chronically, and usually acetylsalicylic acid is the choice. Most often, the treatment is started with phlebotomy in order to rapidly lower the hematocrit level. If cytoreductive therapy is necessary, the drugs of first choice are hydroxycarbamide and interferon [2].
However, the research on the mechanism of the action of interferons is still ongoing. In vitro studies with CD34+ cells from peripheral blood of patients diagnosed with polycythemia vera showed that interferon inhibits clonal changed cells selectively. It was found that interferon alpha-2b and pegylated interferon alpha-2a reduce the percentage of cells with JAK2 V617F mutation by about 40%. Pegylated interferon alpha-2a works by activating mitogen-activated protein kinase P38. It affects CD34+ cells of patients with polycythemia vera by increasing the rate of their apoptosis [6].
A case of a patient with PV with a confirmed chromosomal translocation t(6;8) treated with interferon alpha-2b, which resulted in a reduction of the clone with translocation by 50% from the baseline value, was also described [14].
In 2019, the results of a phase II multicenter study were published, which aimed at assessing the effectiveness of recombinant pegylated interferon alpha-2a in cases of refractory to previously hydroxycarbamide therapy. The study included 65 patients with essential thrombocythemia (ET) and 50 patients with polycythemia vera. All patients had previously been treated with hydroxycarbamide and showed resistance to this drug or its intolerance.
The assessment of the response was performed after 12 months of treatment. Overall response rate to interferon was higher in patients diagnosed with ET than in patients with polycythemia vera. In essential thrombocythemia, the percentage of achieved complete remissions was 43 and 26% of partial remissions. The remission rate in ET patients was higher if calreticulin CALR gene mutation was present. Patients with polycythemia vera achieved complete remission in 22% of cases and partial remission in 38% of cases.
Treatment-related side effects that follow to discontinuation of treatment were reported in almost 14% of patients [15].
The duration of response to treatment with pegylated interferon alpha-2a and the assessment of its safety in long-term use in patients with chronic myeloproliferative disorders was the goal of a phase II of the single-center study. Forty-three adult patients with polycythemia vera and 40 patients with essential thrombocythemia were enrolled in the study. The complete hematological response was defined as a decrease in hemoglobin concentration below 15.0 g/l, without phlebotomies, a resolution of splenomegaly, and no thrombotic episodes in the case of PV, and for essential thrombocythemia—a decrease platelet count below 440,000/μl and two other conditions as above. The assessment of the hematological response was performed every 3–6 months. The median follow-up was 83 months.
The hematological response was obtained in 80% of cases for the entire group. In patients with polycythemia vera, 77% of patients achieved a complete response (CR) while 7% a partial response (PR). The duration of response averaged 65 months for CR and 35 months for PR. In the group of patients diagnosed with essential thrombocythemia, CR was achieved in 73% and PR in 3%. The durance of CR was 58 months and PR was 25 months.
The molecular response for the entire group was achieved in 63% of cases.
The overall analysis showed that the duration of hematological remission and its achievement with pegylated interferon alpha-2a treatment is not affected neither by baseline disease characteristics nor JAK2 allele burden and disease molecular status. There was also no effect on age, sex, or the presence of splenomegaly.
During the course of the study, 22% of patients discontinued the treatment, because of toxicity. Toxicity was the greatest at the beginning of treatment. The starting dose was 450 μg per week and was gradually tapered off.
Thus, on the basis of the above observations, the researchers established that pegylated interferon alpha-2a may give long-term hematological and molecular remissions [16].
The assessment of pegylated interferon alpha-2a in group of patients diagnosed with polycythemia vera only was performed. The evaluation was carried out on a group of 27 patients. Interferon decreased the JAK2 V617F allele burden in 89% of cases. In three patients who were JAK2 homozygous at baseline, after the interferon alpha-2a treatment wild-type of JAK2 reappeared. The reduction of the JAK2 allele burden was estimated from 49% to an average 27%, and additional in one patient the mutant JAK2 allele was not detectable after treatment. It can therefore be postulated that the action of pegylated interferon alpha-2a is directed to cells of the polycythemia vera clone [17].
In 2005, the results of treatment by pegylated interferon alpha-2b of 21 patients diagnosed with polycythemia vera and 21 patients diagnosed with essential thrombocythemia were published. In the case of polycythemia vera in 14 patients, PRV-1 gene mutation was initially detected. In 36% of cases, PRV-1 expression normalized after treatment with pegylated interferon alpha-2b. For the entire group of 42 patients, the remission assessment showed that complete remission was achieved in 69% cases after 6 months of treatment. However, only in 19 patients remission was still maintained 2 years after the start of the study. Pegylated interferon alpha-2b was equally effective in patients with PV and ET. The use and the type of prior therapy did not affect the achievement of remission [18].
Another study with enrolled only PV patients included 136 patients. They were divided into two arms. One group received interferon alpha-2b and the other group received hydroxycarbamide. Interferon dosage was administered in 3 million units three times a week for 2 years and then 5 million units two times a week. Hydroxycarbamide was administered at a dose between 15 and 20 mg/kg/day.
In the group of patients treated with interferon, a significantly lower percentage of patients developed erythromelalgia (9.4%) and distal parasthesia (14%) compared with the group treated with hydroxycarbamide, for whom these percentages were respectively: 29 and 37.5%. Interferon alpha-2b was found to be more effective in inducing a molecular response, which was achieved in 54.7% of cases, in comparison with hydroxycarbamide—19.4% of cases, despite the fact that the percentage of achieved general hematological responses did not differ between the groups and amounted about 70%. The 5-year progression free period in the interferon group was achieved in a higher percentage (66%) than in the hydroxycarbamide group (46.7%) [19].
The most recent form of interferon approved by the
Thanks to these changes to the structure of the molecule, it was possible to achieve a significant increase in its half-life. Ropeginterferon can be administered subcutaneously to patients every 14 days. The clinical trials conducted so far have assessed the ropeginterferon dose from 50 micrograms to a maximum dose of 500 microgams administered as standard every 2 weeks. The possible dose change in case of side effects includes not only the reduction of the drug dose itself, but also the extension of the interval between doses. The extension of the dosing interval up to 4 weeks was assessed.
Ropeginterforn was approved in 2019 by the EMA for the use in patients diagnosed with polycythemia vera without splenomegaly, as monotherapy.
Ropeginterferon, like the previous forms of interferons used in treatment, is contraindicated in patients with severe mental disorders, such as severe depression. It is also a contraindication in patients with noncompensatory standard treatment of disorders of the thyroid gland as well as severe forms of autoimmune diseases. The safety profile of ropeginterferon is similar to that of other forms of alpha interferons. The most common side effects are flu-like symptoms [20].
Ropeginterferon has been shown to exhibit in vitro activity against JAK2-mutant cells. The activity of ropeginterferon against JAK2-positive cells is similar to that of other forms of interferons used actually for standard therapy. Ropeginterferon has an inhibitory effect on erythroid progenitor cells with a mutant JAK2 gene. At the same time, it has almost no effect on progenitor cells without the mutated allele (JAK2-wile-type) and normal CD34+ cells. A gradual decrease of JAK2-positive cells was observed in patients with PV during ropeginterferon treatment. The examination was performed after 6 and 12 months of treatment. In comparison, the reduction in the percentage of JAK2 positive cells in patients treated with hydroxycarbamide was significantly lower.
These results may suggest that ropeginterferon may cause elimination of the mutant clone, but further prospective clinical trials are needed to confirm this theory. The evaluation was performed on a group of patients enrolled in the PROUD-PV study who were treated in France [21].
In 2017, a multicenter study was opened in Italy. The study was of the second phase. In total, 127 patients with polycythemia vera were included in the study. All patients enrolled on the study had low-risk PV. The clinical trial consisted of two arms. Patients received phlebotomies and low-dose aspirin in one arm and ropeginterferon in the other arm. The aim of the study was to achieve a hematocrit of 45% or lower without any evidence of disease progression. Ropeginterferon was administered every 2 weeks at a constant dose of 100 μg.
The response to the treatment was assessed after 12 months. The reduction of hematocrit to the assumed level was achieved in significantly higher percentage of patients in the ropeginterferon group than of patients who received only phlebotomies and aspirin. In addition, none of the patients treated with ropeginterferon experienced disease progression during the course of the study, while among those treated with phlebotomies, 8% of patients progressed.
Grade 4 or 5 adverse events were not observed in patients treated with ropeginterferon, and the incidence of remaining adverse event (AE) was small and comparable in both arms. The most common side effects in the ropeginterferon group were flu-like symptoms and neutropenia; however, the third-grade neutropenia was the most common (8% of cases) [22].
One of the most important clinical studies on the use of ropeginterferon was the PROUD-PV study and its continuation: the CONTINUATION-PV study. These were three-phase, multicenter studies. The aim of the study was to compare the effectiveness of ropeginterferon in relation to hydroxycarbamide. The study included adult patients diagnosed with polycythemia vera treated with hydroxycarbamide for less than 3 years and no cytoreductive treatment at all. In total, 257 patients received this treatment. The patients were divided into two groups: those receiving ropeginterferon or the other being given hydroxycarbamide.
During the PROUD-study, drug doses were increased until the hematocrit was achieved below 45% without the use of phlebotomies, and the normalization of the number of leukocytes and platelets was reached.
The PROUD-PV study lasted 12 months. After this time, the patients continued the treatment under the CONTINUATION-PV study for further 36 months. After the final analysis performed in the 12th month at the end of PROUD study, it was found that the hematological response rates did not differ between the ropeginterferon and hydroxycarbamide treatment groups. These were consecutively 43% in the ropeginterferon arm and 46% in the control arm.
However, after analyzing the CONTINUATION- PV study, it turned out that after 36 months of treatment, the rates of hematological responses begin to prevail in the group of patients receiving ropeginterferon, 53% versus 38% in the control group. Thus, from the above data, it can be seen that the response rate to ropeginterferon increases with the duration of treatment [23].
Another analysis of patients participating in the PROUD and CONTINUATION studies was based on the assessment of treatment results after 24 months, dividing patients into two groups according to age (under and over 60 years).
The initial comparison of both groups of patients showed that older patients had a more aggressive course of the disease. Patients over 60 years of age had a higher percentage of cells with a mutant JAK2 allele. They experienced both general symptoms and some complications, such as thrombosis, more frequently. Both patients under 60 years of age and over 60 years of age in the ropeginterferon arm had a higher rate of molecular response, namely 77.1 and 58.7% compared with the HU remission: 33.3 and 36.1%, respectively. Significantly higher reductions in the JAK2 allele were observed in both groups of patients after ropeginterferon treatment: it was 54.8% for younger patients and 35.1% for elderly patients. For comparison, this difference in the group of patients treated with HU was 4.5 and 18.4%, respectively.
What is more, the age did not affect the frequency of ropeginterferon side effects. In addition, the incidence of adverse ropeginterferon disorders was similar to that observed in the hydroxycarbamide group [24].
Essential thrombocythemia is a clonal growth of multipotential stem cells in the bone marrow. The consequence of this is increased proliferation of megakaryocytes in the bone marrow and an increase in the number of platelets in the peripheral blood. The level of platelets above 450,000/μl is considered a diagnostic criterion.
Essential thrombocythemia may progress over time to a more aggressive form of myeloproliferation, i.e., myelofibrosis. The disease can also evolve into acute myeloid leukemia or myelodysplastic syndrome, both with very poor prognosis. Thromboembolic complications are serious, and they concern over 20% of patients. Thrombosis occurs in the artery and venous area. Moreover, in patients with a very high platelet count, above 1,000,000/μl, bleeding may occur as a result of secondary von Willebrand syndrome [1, 2].
The treatment of ET is primarily aimed to prevent thrombotic complications.
In low-risk patients, only acetylsalicylic acid is used. In cases of high-risk patients, hydroxycarbamide is the first-line drug for most patients. Anagrelide and interferon are commonly used as second-line drugs.
Due to the possible effects of hydroxycarbamide of cytogenetic changes in the bone marrow cells after long-lasting usage, some experts recommend the use of interferon in younger patients in the first line. Interferon is also used as the drug of choice in patients planning a pregnancy [25].
The efficacy of pegylated interferon alpha-2a was assessed on the basis of the group of 39 patients with essential thrombocythemia and 40 patients with polycythemia vera.
Of the overall group, 81% of patients were previously treated prior to the study entry. The patients received pegylated interferon alpha-2a in a dose of 90 μg once a week. The dose of 450 μg was associated with a high percentage of intolerance.
In patients with essential thrombocythemia, the complete remission was achieved in 76%, while the overall hematological response rate brought 81%. Moreover, the molecular remission was achieved in 38%, in 14% of cases, JAK2 transcript became not detectable.
Patients diagnosed with polycythemia vera achieved 70% complete hematological remission and 80% general hematological response to treatment. JAK2 transcript was undetectable in 6% of patients. Molecular remission was achieved in 54% of cases.
Pegylated interferon alpha-2a at the dose of 90 μg per week was very well tolerated. In total, 20% of patients experienced a grade of 3 or 4 of adverse reaction, which was neutropenia. In addition, an increase in liver function tests was observed. Grade 4 of AE was not observed among patients who started the treatment with 90 μg/week while grade 3 neutropenia was an adverse event in only 7% of cases [26].
The effect of interferon alpha-2b treatment in patients with ET and PV was investigated. The study was prospective. Some of the results concerning the group of patients with polycythemia vera are presented in the subsection on polycythemia vera. In total, 123 patients with diagnosed essential thrombocythemia participated in the study. All of them received interferon alpha-2b. The patients were divided into two groups depending on the presence of the JAK2 V617F mutation. The enrolled patients were between 18 and 65 years of age. The treatment they received was, sequentially, interferon alpha-2b in the dose of 3 million units three times a week for the first 2 years, after which time the dose was changed into a maintenance dose, which amounted to 5 million units two times a week.
The analysis showed that the patients with the JAK2 V617F mutation present in a higher percentage achieved an overall hematological response as well as a complete hematological response. The overall hematological response was achieved in 83% of patients with JAK2 mutation, and the complete hematological remission was achieved in 23 cases. In the group of ET patients without the JAK2 V617F mutation, overall hematological response was achieved in 61.4%, while the complete hematological remission was achieved in 12 patients. The 5-year progression-free survival was obtained in 75.9% in the JAKV617F group and only in 47.6% without the mutation.
A significant proportion of patients experienced mild side effects. Grade 3 and 4 of adverse events were severe, most of them being a fever. The isolated cases of elevated liver tests and nausea have also been reported [19].
Pegylated interferon alpha-2b in patients with essential thrombocythemia who were previously treated with hydroxycarbamide, anagrelide, and other forms of interferon alpha, however, due to the lack of efficacy or toxicity, the patients required a change of treatment, was assessed. Pegylated interferon alpha-2b turned out to be effective in these cases. It led to the complete hematological remission in 91% of patients after 2 months of therapy, and in 100% of patients after 4 months. However, merely 11 patients participated in the study. Also only two patients required treatment discontinuation due to the side effects such as depression and general fatigue grade 3 [27].
In case of pregnant patients, interferon is currently considered the only safe cytoreductive drug. Over the years, several analyses of the results of interferon treatment during pregnancy have been carried out.
The assessment of 34 pregnancies in 23 women diagnosed with ET was performed retrospectively. All the pregnancies included in the analysis were of high risk. This high risk was associated with a high platelet count above 1,500,000/μl, a history of thrombotic episode, severe microcirculation disorders, or a history of major hemorrhage.
It turned out that the use of interferon allowed the birth of an alive child in 73.5% of cases. There was no difference in efficacy between the basic and pegylated forms of interferon alpha. In pregnancies without interferon treatment, the percentage of live births was only 60%. Moreover, it was not found if the presence of the JAK2 V617F mutation had any influence on the course of pregnancy [28].
An analysis of the course of pregnancy in patients with ET was assessed in Italy. Data from 17 centers were taken into account. Data from 122 pregnancies were collected from 92 women. In patients diagnosed with essential thrombocythemia, the risk of the spontaneous loss of pregnancy is about 2.5 times higher than among the general population. In the contrary to the study quoted above, it was found that the presence of the JAK2 mutation increases the risk of pregnancy loss. The proportion of live births in patients exposed to interferon during pregnancy was 95%, compared with 71.6% in the group of patients not treated with interferon.
The multivariate analysis also showed that the use of acetylsalicylic acid during pregnancy had no effect on the live birth rate of patients with ET [29].
Whatever its form, interferon is the drug of first choice in pregnancy. Hydroxycarbamide and anagrelide should be withdrawn for about 6 months, and at least for 3 months, before the planned conception. Experts recommend the use of interferon in high-risk pregnancies [30]. A Japanese analysis of 10 consecutive pregnancies in ET patients showed 100% live births in patients who received interferon [31].
In myelofibrosis (MF), monoclonal megakaryocytes produce cytokines that stimulate the proliferation of normal, non-neoplastic fibroblasts and stimulate angiogenesis. The consequence of this is the gradual fibrosis of the bone marrow, impaired hematopoiesis in the bone marrow, and the formation of extramedullary location mainly in the sites of fetal hematopoiesis, i.e., in the spleen and the liver.
The production of various cytokines by neoplastic megakaryocytes leads to the proliferation of normal, noncancerous fibroblasts as well as to increased angiogenesis.
Progressive bone marrow fibrosis leads to worsening anemia and thrombocytopenia. On the other hand, the production of proinflammatory cytokines by megakaryoblasts leads to the general symptoms such as weight loss, fever, joint pain, night sweats, and consequently, progressive worsening of general condition.
The prognosis for myelofibrosis is poor. In about 20% of patients, myelofibrosis evolves into acute myeloid leukemia with poor prognosis.
Currently, the only effective method of treatment that gives a chance to prolong the life is allogeneic bone marrow transplantation. However, this method is only available to younger patients.
The goal of treatment of patients who have not been qualified for allotranspalntation is to reduce the symptoms and to improve the patient’s quality of life. In case of leukocytosis cytoreducing drugs, such as hydroxycarbamide, melphalan, or cladribine can be used. They cause a reduction in the number of leukocytes and may, to some extent, inhibit splenomegaly. Interferon alpha has been used successfully for the treatment of myelofibrosis for many years. The results of its effectiveness will be presented below [2].
Currently, the JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis with enlarged spleen in intermediate and high-risk patients. Ruxolitinib reduces the size of the spleen, reduces general symptoms, and improves the quality of life; however, it does not prolong the overall survival of patients [32].
In 2015, the results of a retrospective study were published to compare the histological parameters of the bone marrow before and after interferon treatment. Twelve patients diagnosed with primary myelofibrosis as well as post-PV MF and post-ET MF were enrolled in the study. Patients were treated with pegylated recombinant interferon alpha-2a or recombinant interferon alpha-2b in standard doses. The time of treatment was from 1 to 10 years. Some patients had previously been treated with hydroxycarbamide or anagrelide. In all cases, karyotype was normal. The prognostic factor of Dynamic International Prognostic Scoring System (DIPSS) was assessed at the beginning as well as during the treatment.
Bone marrow cellularity decreased in cases with increased bone marrow cellularity before the treatment. After the interferon treatment, a reduction in the degree of bone marrow fibrosis was found. The parameters, such as the density of naked nuclei and the density of megakaryocytes in the bone marrow, also improved.
It proves that if the JAK2 V617F mutation had been present, DIPSS was decreased after interferon treatment. This relationship was not observed in patients without the JAK2 V617F mutation. The improvement in peripheral blood morphological parameters and the overall clinical improvement correlated with the improvement in the assessed histological parameters of the bone marrow.
Before the initiation of interferon, seven patients had splenomegaly. During the treatment with interferon, the complete resolution of splenomegaly was achieved in 17% of patients (two cases), and its size decreased in 25% (three cases). A good clinical response was achieved in 83% during interferon therapy. There was no significant difference in response between the two types of interferon used [33].
A prospective study was also conducted in patients with low and intermediate-1 risk group myelofibrosis. Seventeen patients were enrolled. Patients received interferon alpha-2b (0.5–3 milion units/three times a week) or pegylated interferon alpha-2a (45–90 μg/week). The duration of therapy was on average 3.3 years.
Most of the patients responded to the treatment. Partial remission was found in seven patients and complete remission in two patients. Moreover, in four cases, the disease was stabilized and in one case the clinical improvement was achieved. Three patients did not respond to treatment at all and progressed to myelofibrosis. Additionally, the assessment in reducing spleen size was performed. At baseline, 15 patients have splenomegaly, nine of them achieved the compete regression of spleen size [34].
However, the efficacy of interferon in the treatment of myelofibrosis appears to be limited only to a less advanced form, when the bone marrow still has an adequate percentage of normal hemopoiesis and the marrow stroma is not significantly fibrotic. In more advanced stages, interferon was not shown to have any significant effect on the regression of the fibrosis process [35].
In 2020, the results of the COMBI study were published. That was a two-phase, multicenter, single-arm study that investigated the efficacy and safety of the combination of ruxolitinib and pegylated interferon alpha. Thirty-two patients with PV and 18 patients with primary and secondary myelofibrosis participated in the study. The patients were at age 18 and older. Remission was achieved in 44% of myelofibrosis cases, including 28% (5 patients) of complete remission. In patients with PV, the results were slightly worse: 31% of remissions, including 9% of complete remissions. Patients received pegylated interferon alpha-2a (45 μg/week) or pegylated interferon alpha-2b (35 μg/week) in low doses and ruxolitinib in doses of 5–20 mg twice a day.
For the entire group of patients (with PV and MF), the initial JAK2 allele burden was 47% at baseline, and after 2 years of treatment with interferon and ruxolitinib, it decreased to 12%.
The treatment toxicity was low. The highest incidence of side effects occurred at initiation of therapy. It was mostly anemia and thrombocytopenia.
The observations from the COMBI study show that, for the combination of interferon in lower doses with ruxolitinib, it may be effective and well tolerated even in the group of patients who had intolerance to interferon used as the only drug in higher doses. The combined treatment improved the bone marrow in terms of fibrosis and its cellularity. It also allowed to improve the value of peripheral blood counts [36].
It is currently known that some of the additional mutations are associated with a worse prognosis in patients with myelorpoliferation, including patients with myelofibrosis. Some of these mutations have been identified as high-risk molecular mutations. These are ASXL1, EZH2, IDH1/2, or SRSF2. Earlier studies have shown their association with a more aggressive course of the disease, worse prognosis, and shorter survival of patients, as well as a poorer response to treatment. Due to their importance, they have been included in the diagnostic criteria of myelofibrosis [37].
It is also known that the presence of driver mutations, i.e., JAK2, CALR, and MPL or triple negativity, may affect the course of myeloproliferation, including the incidence of thromboembolic complications.
The assessment of the influence of driver mutations and a panel of selected additional mutations on the effectiveness of interferon treatment in patients with myelofibrosis was performed on a group of 30 patients. Only the patients with low- and intermediate-1-risk were enrolled in the study. The treatment with pegylated interferon alpha-2a or interferon alpha-2b resulted in a complete remission in two patients and partial remission in nine patients. The disease progressed in three cases. One patient relapsed and four died. The remaining patients achieved a clinical improvement or disease stabilization. In the studied group, it was not found if the effectiveness of interferon treatment was influenced by the lack of driver mutations. Among the group of four patients with additional mutations, two died and one had disease progression. It was a mutation of ASXL1 and SRSF2. The treatment with interferon in patients without additional molecular mutations in the early stages of the disease may prevent further progression of the disease [38].
The side effects of interferon in the group of patients with myelofibrosis are similar to those occurring after the treatment of other chronic myeloproliferative diseases. The most frequently described are hematological toxicity- anemia and thrombocytopenia, less often is the appearance of leukopenia. Hematological toxicity usually resolves with dose reduction or extension of the dose interval. The most frequently nonhematological toxicity was fatigue, muscle pain, weakness, and depression symptoms. All symptoms are usually mild and do not exceed grade 2 [38].
However, the use of interferon in the treatment of myelofibrosis has not been recommended as a standard therapy. Interferon is still being evaluated in clinical trials, or it is used in selected patients as a nonstandard therapy in this diagnosis.
Mastocytosis is characterized by an excessive proliferation of abnormal mast cells and their accumulation in various organs.
The basis for the development of mastocytosis is ligand-independent activation of the KIT receptor, resulting from mutations in the KIT proto-oncogene. The KIT receptor is a trans membrane receptor with tyrosine kinase’s activity. Its activation stimulates the proliferation of mast cells. That excessive numbers of mast cells infiltrate tissues and organs and release mediators such as histamine, interleukine-6, tryptase, heparin, and others, which are responsible for the appearance of symptoms typical of mastocytosis. In addition, the infiltration of tissues for mast cells itself causes damage to the affected organs.
The prognosis of mastocytosis depends on the type of the disease. In the case of cutaneous mastocytosis (CM), in the majority of cases prognosis is good and the disease does not shorten the patient’s life, but in aggressive systemic mastocytosis (ASM), the average follow-up is about 40 months. Mast cell leukemia has a poor prognosis with a median follow-up of approximately 1 year.
Systemic mastocytosis usually requires the implementation of cytoreductive therapy. The first line of therapy is interferon alone or its combination with corticosteroids. In aggressive systemic mastocytosis, the first line in addition to interferon 2-CdA can be used. An effective drug turned out to be midostaurin in the case of the present KIT mutation. In patients without the KIT D816V mutation, treatment with imatinib may be effective. In the case of mast cell leukemia, multidrug chemotherapy is most often required, as in acute leukemias, followed by bone marrow transplantation [39].
Systemic mastocytosis requiring treatment is a rare disease, this is why the studies available in the literature evaluating various therapies concern mostly small groups of patients.
In 2002, the French authors presented their experiences on the use of interferon in patients with systemic mastocytosis. They included 20 patients. The patients received interferon alpha-2b in gradually increased doses.
The patients were assessed after 6 months. In cases in which bone marrow was infiltrated for mast cells at baseline, it still remained infiltrated after 6 months of treatment.
However, the responses were obtained in terms of symptoms related to mast cell degranulation. Partial remission was achieved in 35% of patients and minor remission in 30%. It concerns mainly skin lesions and vascular congestion. Moreover, the assessment of the histamine level in the plasma revealed a decrease of it in patients who previously presented symptoms related to the degranulation of mast cells, such as gastrointestinal disorders and flushing.
A high percentage of side effects were found during treatment. They concerned 35% of patients. Depression and cytopenia were most frequent ones [40].
Another analysis was a report of five patients with systemic mastocytosis treated with interferon and prednisolone. All patients received interferon alpha-2b in a dose of 3 million units three times a week and four patients additionally received prednisolone. Four patients responded to interferon treatment at varying degrees. One patient, who at baseline had bone marrow involvement by mast cells in above 10%, progressed to mast cell leukemia. In two patients, the symptoms C resolved completely and in one of them they partially disappeared. In one case, stabilizing disease was achieved [41].
In 2009, a retrospective analysis of patients treated with cytoreductive therapy due to mastocytosis was published. The authors collected data from 108 patients treated at the Mayo Clinic. This analysis allowed for the comparison of the efficacy of four drugs used in systemic mastocytosis. There were interferon alpha alone or in the combination with prednisone—among 40 patients, hydroxycarbamide—among 26 ones, imatinib—among 22 persons, and 2-chlorodeoxyadenosine (2-CdA)—among 22 patients.
After dividing the patients into three additional groups on the basis of the type of mastocytosis—indolent systemic mastocytosis, aggressive systemic mastocytosis, and systemic mastocytosis associated with another clonal hematological nonmast cell lineage disease (SM-AHNMD)—the effectiveness of each of type of therapy was assessed.
The highest response rates in indolent and aggressive mastocytosis were achieved with interferon treatment. They were 60% of the responses in both groups, and in the SM-AHNMD group of patients, the percentage was also one of the highest and amounted to 45%. The second most effective drug was 2-CdA. The response rates were 56% for indolent MS, 50% for aggressive MS, and 55% for SM-AHNMD. The patients treated with imatinib achieved response in 14, 50, and 9% by following groups, respectively. In contrast, patients with indolent and aggressive systemic mastocytosis did not respond to hydroxycarbamide treatment at all. The response rate in both groups was 0%. However, patients with MS associated with another clonal hematological nonmast cell lineage disease achieved 21% response to hydroxycarbamide. Additionally, it was found that only interferon relieved symptoms caused by the release of inflammatory mediators by mast cells.
The additional analysis showed no influence of the TET 2 mutation on the response to treatment [42].
In the literature, there are also single cases of mastocytosis presenting trials of nonstandard treatment. That is description of a patient with systemic mastocytosis with mast cell bone marrow involvement. Mutation of c-kit Asp816Val was present. Patient progressed despite treatment with dasatinib and 2-chlorodeoxyadenosine. The patient developed symptoms related to the degranulation of mast cells and increased ascites.
The patient was treated with pranlukast, which is an anti-leukotriene receptor antagonist due to an asthma episode. The rate of ascites growth decreased significantly after one administration. The patient required paracentesis every 10 days and not every 3 days, as before starting to take the drug. After 15 days of treatment with pranlukast, the patient received interferon alpha, which resulted in complete regression of ascites, resolution of pancytopenia, and complete disappearance of the c-kit mutation clone. The infiltration of mast cells in the bone marrow significantly decreased [43].
Interferon alpha was also effective in a patient with systemic mastocytosis associated with myelodysplastic syndrome with the c-kit D816V mutation, which was refractory to imatinib treatment [44].
Interferon alpha also proved to be effective in the treatment of osteoporotic lesions appearing in the course of mastocytosis.
The series of 10 cases with resolved mastocytosis and osteoporosis-related fractures was presented in 2011. The patients received interferon alpha in a dose of 1.5 million units three times a week as well as pamindronic acid. The patients were treated for an average of 60 months. For the first 2 years, pamindronate was given at a dose of 1 mg/kg every month, and then every 3 months.
During the course of the study, no patient had a new-bone fracture. The level of alkaline phosphatase decreased by 25% in relation to the value before treatment and tryptase by 34%. Bone density increased during treated with interferon and pamindronate. The increase was on average 12% in the spine bones and 1.9% in the hip bones. At the same time, there was no increase in the density of the hip bone and a minimal increase in the density of the spine in patients treated with pamindronate alone.
The results of this observation suggest that it is beneficial to add low doses of interferon alpha to pamindronate treatment in terms of bone density increase [45].
That experiences show that interferon used in systemic mastocytosis significantly improves the quality of life of patients by inhibiting the symptoms caused by degranulation of mast cells. They prevent bone fractures and, in some patients, they cause remission of bone marrow infiltration by mast cells.
Chronic neutrophilic leukemia (CNL) is a very rare disease. It is characterized by the clonal proliferation of mature neutrophils.
The diagnostic criteria proposed by the World Health Organization (WHO) comprise leukocyte counts above 25,000/μl (including more than 80% of rod and segmented
Physical examination often shows enlargement of the liver and spleen, moreover, patients complain on weight loss and weakness [1].
The prognosis varies. The average survival time for patients with CNL is less than 2 years.
Only few descriptions of chronic neutrophilic leukemia are available in the literature, and these are mostly single case reports.
Because it is an extremely rare disease, there are no established and generally accepted treatment standards. In most cases, patients are given hydroxycarbamide or interferon. Patients who are eligible for a bone marrow transplant may benefit from this treatment. Bone marrow allotransplantation remains the only method that gives a chance for a significant extension of life.
The German authors presented a series of 14 cases of chronic neutrophilic leukemia. The group of patients consisted of eight women and six men. The average age was 64.7 years. From the entire group of patients, longer survival was achieved only in three cases. One of these patients was treated with interferon alpha and achieved hematological remission, the other underwent bone marrow allotransplantation from a family donor, and the third one was treated with hydroxycarbamide and transfusions as needed. The follow-up period of the patient after allogeneic matched related donor transplantation (allo-MRD) was 73 months, and for the patient after interferon treatment it was 41 months.
The remaining patients died within 2 years of diagnosis. Six patients, the largest group, died due to intracranial bleeding, three patients died because of leukemia cell tissue infiltration, one patient because of the disease transformation into leukemia, and one patient because of pneumonia [46].
It can be seen from these experiences that treatment with interferon alpha can significantly extend the survival time of patients.
The case of a 40-year-old woman diagnosed with chronic neutrophilic leukemia is presented by Yassin and coauthors. Initially, the patient had almost 41,000 leukocytes in the peripheral blood. In a physical examination, splenomegaly and hepatomegaly were not present. Patient received pegylated interferon alpha-2a. The initially dose was 50 μg once a week for the first 2 weeks, then the dose was increased to 135 μg weekly for 6 weeks, and then the dose interval was extended to another 2 weeks. As a result of the treatment, the general condition of the patient improved and the parameters of peripheral blood counts were normalized [47].
Another case report presented in the literature describes a 41-year-old woman diagnosed with CNL accompanied by focal segmental glomerulosclerosis (FSGS). The patient had increasing leukocytosis for several months. On the admission to the hospital, leukocytosis was 94,000/μl. Moreover, the number of platelets in the morphology exceeded 1,000,000/μl. More than a year earlier, the patient had splenectomy due to splenomegaly and spleen infraction.
Additionally, JAK2 V617F mutation was found. Some authors suggest that the presence of JAK2 mutation may be associated with longer survival in CNL.
The patient received hydroxycarbamide for 3 months and reduction in the number of leukocytes was achieved. After this time, interferon alpha-2b was added to hydroxycarbamide. As a result, focal segmental glomerulosclerosis disappeared and the renal tests improved [48].
Another case of chronic neutrophilic leukemia with a JAK2 gene mutation concerns a 53-year-old man. The patient’s baseline leukocytosis was 33,500/μl, including the neutrophil count of 29,700/μl. The patient also had splenomegaly.
The treatment with interferon alpha-2b at a dose of 3 million units every other day was started. After a month of treatment, the number of leukocytes was reduced to less than 10,000/μl. Then the patient was treated chronically with interferon alpha-2b in doses of 3 million units every 2 weeks. As a result of the therapy, the number of leukocytes remains between 8 and 10,000/μl. The patient remains in general good condition [49].
A series of two CNL cases are also shown. The first patient was a 70-year-old woman with stable leukocytosis of about 35,000/μl and the remaining morphology parameters in normal range. The patient was only observed for 5 years until hepasplenomegaly progressed rapidly. Then, interferon alpha-2b was included. Due to the treatment, the rapid regression of hepatosplenomegaly was achieved.
The second case is a 68-year-old woman with baseline leukocytosis of almost 14,000/μl. In this case, the treatment with hydroxycarbamide was started immediately. However, no improvement was achieved. After 6 weeks of HU treatment, interferon alpha-2b 3 million units 3 times a week was implemented and leukocytosis decreased. Due to the interferon treatment, the disease stabilized for a long time. Because the patient experienced an adverse reaction, a severe flu-like syndrome, interferon was discontinued. After interferon withdrawal, the disease progressed gradually and the treatment attempts by busulfan and 6-mercaptopurine were unsuccessful. Therefore, interferon was readministered and the disease went into remission. Interferon treatment was continued at a reduced dose. The disease regression was achieved again.
Additionally, the patient showed an improvement in the function of granulocytes in terms of phagocytosis and an improvement in neutral killer (NK) cell function after treatment with interferon [50].
The above examples show that interferon alpha is effective in the treatment of chronic neutrophilic leukemia. The side effects are rare and can be managed with dose reductions. Moreover, in these cases, interferon is also effective in a reduced dose. Disease remission or regression can be achieved without typical of CNL complications, such as intracranial bleeding.
Interferon has been used in the past to treat chronic myeloid leukemia. The treatment with tyrosine kinase inhibitors is now a standard practice. However, in a small number of patients, they are ineffective or exhibit unmanageable toxicity. Therefore, the attempts are underway to use interferon in combination with TKI in lower doses, which is to ensure the enhancement of the antiproliferative effect while reducing the toxicity.
There are ongoing attempts to use ropeginterferon in patients diagnosed with chronic myeloid leukemia, in whom treatment with imatinib alone has not led to deep molecular response (DMR). The first phase study was conducted in a small group of patients with chronic myeloid leukemia. The patients in first chronic phase treated with imatinib who did not achieve DMR, but in complete hematologic remission and complete cytogenetic remission, were included in the study. Patients have been treated with imatinib for at least 18 months. Twelve patients were enrolled in the study, and they completed the study according to the protocol. These patients received additional ropeginterferon to imatinib and four achieved DMR. Low toxicity was observed during the treatment. Among the hematological toxicities, neutropenia was the most common. There was no nonhematological toxicity with a degree higher than 1/2 during the treatment. Moreover, it has been found that better effects and fewer side effects are obtained when ropeginterferon is administered for a longer time, but in lower doses. The comparison of the effectiveness of interferon in chronic myeloproliferative disorders based on selected articles is presented in Table 1 [51].
Source | Type of trial | Interferon | Diagnosis | No. | Prior treatment status | Response rate |
---|---|---|---|---|---|---|
Yacoubet al. [15] | Phase II, multicenter | Pegylated IFN alfa-2a | PV | 50 | Resistance to HU or HU intolerance | CR:22% PR:38% |
ET | 65 | CR:43% PR:26% | ||||
Masarova et al. [16] | Phase II, single-center | Pegylated IFN alfa-2a | PV | 43 | Untreated or previously treated with cytoreductive therapy | CR:77% PR:7% |
ET | 40 | CR:73% PR:3% | ||||
Samuelsson et al. [18] | Phase II | Pegylated IFN alfa-2b | PV | 21 | Untreated or previously treated with cytoreductive therapy | CR: 69% for the entire group |
ET | 21 | |||||
Huang BT et al. [19] | Open label, multicenter | IFN alfa-2b | PV | 136 | Untreated or previously treated with cytoreductive therapy | OHR:70% Molecular response:54.7% |
ET | 123 | OHR (JAK2+ patients):83% CHR:23 cases OHR (JAK2-patients): 61.4% CHR:12 cases | ||||
Gisslinger et al. [23] | phase III, multicenter | Ropeginterferon | PV | 257 | Previously treated | OHR:53% |
Quintás-Cardama et al. [26] | phase II | Pegylated IFN alfa-2a | PV | 40 | Untreated or previously treated with cytoreductive therapy | OHR:80% CR:70% Molecular remission:54% |
ET | 39 | OHR:81% CR:76% Molecular remission:38% | ||||
Sørensen et al. [36] | Phase III, multicenter, COMBI | Pegylated IFN alfa-2a with ruxolitinib or Pegylated IFN alfa-2b with ruxolitinib | PV | 32 | Untreated or previously treated with cytoreductive therapy | OHR:44% CR:28% |
MF | 18 | OHR:31% CR:9% | ||||
Casassus et al. [40] | Open label, multicenter | IFN alpha-2b | Mastocytosis | 20 | Untreated and previously treated | PR:35% Minor remission: 30% |
Comparison of the effectiveness of interferon in chronic myeloproliferative disorders.
PV: polycythemia vera; ET: essential thrombocythemia; MF: myelofibrosis; HU: hydroxycarbamide/hydroxyurea; CR: complete remission; PR: partial remission; and OHR: overall hematological response.
Interferon alpha appears to be an effective and safe drug in the most type of chronic myeloproliferative disorders. Nowadays, all forms of its using have similar effectiveness. Interferon alpha can be effective even in cases of resistance for first-line treatment. Trial research is currently underway to combine it with some new drugs, such as ruxolitinib, and to add it to the already well-established therapy, it is a promising option for patients with refractory disease.
From time to time, new forms of interferon, such as ropeginterferon, are introduced, which gives hope for better effectiveness, better safety profile, and greater comfort in its use for patients who have to be treated for many years. In the case of the use of interferons alpha in the treatment of chronic myeloproliferative diseases, there are still opportunities to extend its use and to study its combination with newly introduced drugs.
General requirements for Open Access to Horizon 2020 research project outputs are found within Guidelines on Open Access to Scientific Publication and Research Data in Horizon 2020. The guidelines, in their simplest form, state that if you are a Horizon 2020 recipient, you must ensure open access to your scientific publications by enabling them to be downloaded, printed and read online. Additionally, said publications must be peer reviewed.
',metaTitle:"Horizon 2020 Compliance",metaDescription:"General requirements for Open Access to Horizon 2020 research project outputs are found within Guidelines on Open Access to Scientific Publication and Research Data in Horizon 2020. The guidelines, in their simplest form, state that if you are a Horizon 2020 recipient, you must ensure open access to your scientific publications by enabling them to be downloaded, printed and read online. Additionally, said publications must be peer reviewed. ",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"Publishing with IntechOpen means that your scientific publications already meet these basic requirements. It also means that through our utilization of open licensing, our publications are also able to be copied, shared, searched, linked, crawled, and mined for text and data, optimizing our authors' compliance as suggested by the European Commission.
\\n\\nMetadata for all publications is also automatically deposited in IntechOpen's OAI repository, making them available through the Open Access Infrastructure for Research in Europe's (OpenAIRE) search interface further establishing our compliance.
\\n\\nIn other words, publishing with IntechOpen guarantees compliance.
\\n\\nRead more about Open Access in Horizon 2020 here.
\\n\\nWhich scientific publication to choose?
\\n\\nWhen choosing a publication, Horizon 2020 grant recipients are encouraged to provide open access to various types of scientific publications including monographs, edited books and conference proceedings.
\\n\\nIntechOpen publishes all of the aforementioned formats in compliance with the requirements and criteria established by the European Commission for the Horizon 2020 Program.
\\n\\nAuthors requiring additional information are welcome to send their inquiries to funders@intechopen.com
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Publishing with IntechOpen means that your scientific publications already meet these basic requirements. It also means that through our utilization of open licensing, our publications are also able to be copied, shared, searched, linked, crawled, and mined for text and data, optimizing our authors' compliance as suggested by the European Commission.
\n\nMetadata for all publications is also automatically deposited in IntechOpen's OAI repository, making them available through the Open Access Infrastructure for Research in Europe's (OpenAIRE) search interface further establishing our compliance.
\n\nIn other words, publishing with IntechOpen guarantees compliance.
\n\nRead more about Open Access in Horizon 2020 here.
\n\nWhich scientific publication to choose?
\n\nWhen choosing a publication, Horizon 2020 grant recipients are encouraged to provide open access to various types of scientific publications including monographs, edited books and conference proceedings.
\n\nIntechOpen publishes all of the aforementioned formats in compliance with the requirements and criteria established by the European Commission for the Horizon 2020 Program.
\n\nAuthors requiring additional information are welcome to send their inquiries to funders@intechopen.com
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr.",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Rheinmetall (Germany)",country:{name:"Germany"}}},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:13389},{group:"region",caption:"Middle and South America",value:2,count:11661},{group:"region",caption:"Africa",value:3,count:4168},{group:"region",caption:"Asia",value:4,count:22334},{group:"region",caption:"Australia and Oceania",value:5,count:2019},{group:"region",caption:"Europe",value:6,count:33642}],offset:12,limit:12,total:135275},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish"},books:[{type:"book",id:"11369",title:"RNA Viruses Infection",subtitle:null,isOpenForSubmission:!0,hash:"52f8a3a1486912beae40b34ac557fed3",slug:null,bookSignature:"Ph.D. Yogendra Shah",coverURL:"https://cdn.intechopen.com/books/images_new/11369.jpg",editedByType:null,editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11027",title:"Basics of Hypoglycemia",subtitle:null,isOpenForSubmission:!0,hash:"98ebc1e36d02be82c204b8fd5d24f97a",slug:null,bookSignature:"Dr. Alok Raghav",coverURL:"https://cdn.intechopen.com/books/images_new/11027.jpg",editedByType:null,editors:[{id:"334465",title:"Dr.",name:"Alok",surname:"Raghav",slug:"alok-raghav",fullName:"Alok Raghav"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11124",title:"Next-Generation Textiles",subtitle:null,isOpenForSubmission:!0,hash:"093f9e26bb829b8d414d13626aea1086",slug:null,bookSignature:"Dr. Hassan Ibrahim",coverURL:"https://cdn.intechopen.com/books/images_new/11124.jpg",editedByType:null,editors:[{id:"90645",title:"Dr.",name:"Hassan",surname:"Ibrahim",slug:"hassan-ibrahim",fullName:"Hassan Ibrahim"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11610",title:"New Insights in Herbicide Science",subtitle:null,isOpenForSubmission:!0,hash:"eb3830b8176caf3d1fd52c32313c5168",slug:null,bookSignature:"Ph.D. Kassio Ferreira Mendes",coverURL:"https://cdn.intechopen.com/books/images_new/11610.jpg",editedByType:null,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11561",title:"Zeolite From Wastes - New Perspectives on Innovative Resources and Their Valorization Process",subtitle:null,isOpenForSubmission:!0,hash:"3ed0dfd842de9cd1143212415903e6ad",slug:null,bookSignature:"Dr. Claudia Belviso",coverURL:"https://cdn.intechopen.com/books/images_new/11561.jpg",editedByType:null,editors:[{id:"61457",title:"Dr.",name:"Claudia",surname:"Belviso",slug:"claudia-belviso",fullName:"Claudia Belviso"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11814",title:"Liposomes - Recent Advances, New Perspectives and Applications",subtitle:null,isOpenForSubmission:!0,hash:"62d8542d18b8cddcf507f7948b2ae74b",slug:null,bookSignature:"Dr. Rajeev K. Tyagi",coverURL:"https://cdn.intechopen.com/books/images_new/11814.jpg",editedByType:null,editors:[{id:"269120",title:"Dr.",name:"Rajeev",surname:"Tyagi",slug:"rajeev-tyagi",fullName:"Rajeev Tyagi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11709",title:"Type 1 Diabetes Mellitus",subtitle:null,isOpenForSubmission:!0,hash:"cc0e61f864a2a8a9595f4975ce301f70",slug:null,bookSignature:"Dr. Shilpa Mehta and Dr. Resmy Palliyil Gopi",coverURL:"https://cdn.intechopen.com/books/images_new/11709.jpg",editedByType:null,editors:[{id:"342545",title:"Dr.",name:"Shilpa",surname:"Mehta",slug:"shilpa-mehta",fullName:"Shilpa Mehta"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11778",title:"Correctional Facilities and Correctional Treatment - International Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"a933550a6966a04e4677a4c0aea8f5b2",slug:null,bookSignature:"Prof. Rui Abrunhosa Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/11778.jpg",editedByType:null,editors:[{id:"198691",title:"Prof.",name:"Rui",surname:"Abrunhosa Gonçalves",slug:"rui-abrunhosa-goncalves",fullName:"Rui Abrunhosa Gonçalves"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11889",title:"Sexual Disorders and Dysfunctions",subtitle:null,isOpenForSubmission:!0,hash:"b988fda30a4e2364ee9d47e417bd0ba9",slug:null,bookSignature:"Dr. Dhastagir Sultan Sheriff",coverURL:"https://cdn.intechopen.com/books/images_new/11889.jpg",editedByType:null,editors:[{id:"167875",title:"Dr.",name:"Dhastagir Sultan",surname:"Sheriff",slug:"dhastagir-sultan-sheriff",fullName:"Dhastagir Sultan Sheriff"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11867",title:"Echocardiography",subtitle:null,isOpenForSubmission:!0,hash:"d9159ce31733bf78cc2a79b18c225994",slug:null,bookSignature:"Dr. Gabriel Cismaru",coverURL:"https://cdn.intechopen.com/books/images_new/11867.jpg",editedByType:null,editors:[{id:"191888",title:"Dr.",name:"Gabriel",surname:"Cismaru",slug:"gabriel-cismaru",fullName:"Gabriel Cismaru"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11948",title:"Field-Effect Transistor",subtitle:null,isOpenForSubmission:!0,hash:"bb6fc82b35ad2c63618a9bc15aeb61ce",slug:null,bookSignature:"Dr. Kim Ho Yeap and Dr. Magdalene Goh Wan Ching",coverURL:"https://cdn.intechopen.com/books/images_new/11948.jpg",editedByType:null,editors:[{id:"24699",title:"Dr.",name:"Kim Ho",surname:"Yeap",slug:"kim-ho-yeap",fullName:"Kim Ho Yeap"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12019",title:"Chaos Theory - Recent Advances, New Perspectives and Applications",subtitle:null,isOpenForSubmission:!0,hash:"38f0946fe1dd3314939e670799f88426",slug:null,bookSignature:"Dr. Mykhaylo I. Andriychuk",coverURL:"https://cdn.intechopen.com/books/images_new/12019.jpg",editedByType:null,editors:[{id:"57755",title:"Dr.",name:"Mykhaylo",surname:"Andriychuk",slug:"mykhaylo-andriychuk",fullName:"Mykhaylo Andriychuk"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:24},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:7},{group:"topic",caption:"Business, Management and Economics",value:7,count:4},{group:"topic",caption:"Chemistry",value:8,count:16},{group:"topic",caption:"Computer and Information Science",value:9,count:18},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:8},{group:"topic",caption:"Engineering",value:11,count:39},{group:"topic",caption:"Environmental Sciences",value:12,count:5},{group:"topic",caption:"Immunology and Microbiology",value:13,count:8},{group:"topic",caption:"Materials Science",value:14,count:15},{group:"topic",caption:"Mathematics",value:15,count:9},{group:"topic",caption:"Medicine",value:16,count:64},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:7},{group:"topic",caption:"Physics",value:20,count:5},{group:"topic",caption:"Psychology",value:21,count:5},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:8},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:251},popularBooks:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3737",title:"MATLAB",subtitle:"Modelling, Programming and Simulations",isOpenForSubmission:!1,hash:null,slug:"matlab-modelling-programming-and-simulations",bookSignature:"Emilson Pereira Leite",coverURL:"https://cdn.intechopen.com/books/images_new/3737.jpg",editors:[{id:"12051",title:"Prof.",name:"Emilson",middleName:null,surname:"Pereira Leite",slug:"emilson-pereira-leite",fullName:"Emilson Pereira Leite"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"1770",title:"Gel Electrophoresis",subtitle:"Principles and Basics",isOpenForSubmission:!1,hash:"279701f6c802cf02deef45103e0611ff",slug:"gel-electrophoresis-principles-and-basics",bookSignature:"Sameh Magdeldin",coverURL:"https://cdn.intechopen.com/books/images_new/1770.jpg",editors:[{id:"123648",title:"Dr.",name:"Sameh",middleName:null,surname:"Magdeldin",slug:"sameh-magdeldin",fullName:"Sameh Magdeldin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4797},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",publishedDate:"July 27th 2022",numberOfDownloads:7175,editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1981,editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",publishedDate:"July 20th 2022",numberOfDownloads:2308,editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1473,editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",publishedDate:"April 26th 2011",numberOfDownloads:318571,editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",publishedDate:"September 26th 2012",numberOfDownloads:271836,editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",publishedDate:"July 1st 2013",numberOfDownloads:243450,editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",publishedDate:"July 20th 2022",numberOfDownloads:1582,editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",publishedDate:"July 13th 2022",numberOfDownloads:2082,editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",publishedDate:"October 17th 2012",numberOfDownloads:256294,editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11328",title:"Botulinum Toxin",subtitle:"Recent Topics and Applications",isOpenForSubmission:!1,hash:"7dd05a316001cef143e209eda51387a7",slug:"botulinum-toxin-recent-topics-and-applications",bookSignature:"Suna Sabuncuoglu",coverURL:"https://cdn.intechopen.com/books/images_new/11328.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"270856",title:"Associate Prof.",name:"Suna",middleName:null,surname:"Sabuncuoglu",slug:"suna-sabuncuoglu",fullName:"Suna Sabuncuoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11085",title:"Polycystic Ovary Syndrome",subtitle:"Functional Investigation and Clinical Application",isOpenForSubmission:!1,hash:"3066dd3ff29e1fac072fd60b08d4d3e7",slug:"polycystic-ovary-syndrome-functional-investigation-and-clinical-application",bookSignature:"Zhengchao Wang",coverURL:"https://cdn.intechopen.com/books/images_new/11085.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"204883",title:"Dr.",name:"Zhengchao",middleName:null,surname:"Wang",slug:"zhengchao-wang",fullName:"Zhengchao Wang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10833",title:"Tumor Angiogenesis and Modulators",subtitle:null,isOpenForSubmission:!1,hash:"f29b575c46128b2da061ef7f9bd1070b",slug:"tumor-angiogenesis-and-modulators",bookSignature:"Ke Xu",coverURL:"https://cdn.intechopen.com/books/images_new/10833.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"59529",title:"Dr.",name:"Ke",middleName:null,surname:"Xu",slug:"ke-xu",fullName:"Ke Xu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11356",title:"Molecular Cloning",subtitle:null,isOpenForSubmission:!1,hash:"671c629dd86e97f0fb467b9e70e92296",slug:"molecular-cloning",bookSignature:"Sadık Dincer, Hatice Aysun Mercimek Takcı and Melis Sumengen Ozdenef",coverURL:"https://cdn.intechopen.com/books/images_new/11356.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"188141",title:"Prof.",name:"Sadik",middleName:null,surname:"Dincer",slug:"sadik-dincer",fullName:"Sadik Dincer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10669",title:"Corrosion",subtitle:"Fundamentals and Protection Mechanisms",isOpenForSubmission:!1,hash:"4a76d54f8a40fc2e7002a8d13fd617c1",slug:"corrosion-fundamentals-and-protection-mechanisms",bookSignature:"Fahmina Zafar, Anujit Ghosal and Eram Sharmin",coverURL:"https://cdn.intechopen.com/books/images_new/10669.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"89672",title:"Dr.",name:"Fahmina",middleName:null,surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Advanced Topics of Topology",subtitle:null,isOpenForSubmission:!1,hash:"bf964c52f9e653fac20a7fcab58070e5",slug:"advanced-topics-of-topology",bookSignature:"Francisco Bulnes",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"92918",title:"Dr.",name:"Francisco",middleName:null,surname:"Bulnes",slug:"francisco-bulnes",fullName:"Francisco Bulnes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11195",title:"Recent Advances in Biometrics",subtitle:null,isOpenForSubmission:!1,hash:"2d32e33e0f499cb5241734bb75dd2a83",slug:"recent-advances-in-biometrics",bookSignature:"Muhammad Sarfraz",coverURL:"https://cdn.intechopen.com/books/images_new/11195.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"986",title:"Clinical Cardiac Electrophysiology",slug:"clinical-cardiac-electrophysiology",parent:{id:"170",title:"Cardiology and Cardiovascular Medicine",slug:"cardiology-and-cardiovascular-medicine"},numberOfBooks:9,numberOfSeries:0,numberOfAuthorsAndEditors:178,numberOfWosCitations:46,numberOfCrossrefCitations:53,numberOfDimensionsCitations:87,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"986",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6536",title:"Cardiac Arrhythmias",subtitle:null,isOpenForSubmission:!1,hash:"60225e652fdad9957fb2bad71795510f",slug:"cardiac-arrhythmias",bookSignature:"Umashankar Lakshmanadoss",coverURL:"https://cdn.intechopen.com/books/images_new/6536.jpg",editedByType:"Edited by",editors:[{id:"13913",title:"Dr.",name:"Umashankar",middleName:null,surname:"Lakshmanadoss",slug:"umashankar-lakshmanadoss",fullName:"Umashankar Lakshmanadoss"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5533",title:"The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure",subtitle:null,isOpenForSubmission:!1,hash:"72992f70d4e3ffcae4aa03439ea54954",slug:"the-role-of-the-clinical-cardiac-electrophysiologist-in-the-management-of-congestive-heart-failure",bookSignature:"John Kassotis",coverURL:"https://cdn.intechopen.com/books/images_new/5533.jpg",editedByType:"Edited by",editors:[{id:"146888",title:"Dr.",name:"John",middleName:null,surname:"Kassotis",slug:"john-kassotis",fullName:"John Kassotis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5216",title:"Update on Essential Hypertension",subtitle:null,isOpenForSubmission:!1,hash:"7f462a8fbbf6a1af402d2689a50a9670",slug:"update-on-essential-hypertension",bookSignature:"Lizbeth Salazar-Sanchez",coverURL:"https://cdn.intechopen.com/books/images_new/5216.jpg",editedByType:"Edited by",editors:[{id:"73775",title:"Dr.",name:"Lizbeth",middleName:null,surname:"Salazar-Sanchez",slug:"lizbeth-salazar-sanchez",fullName:"Lizbeth Salazar-Sanchez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4584",title:"Abnormal Heart Rhythms",subtitle:null,isOpenForSubmission:!1,hash:"81532d7ef92dec2fed90a8c7ea7a051c",slug:"abnormal-heart-rhythms",bookSignature:"Francisco R. Breijo-Marquez",coverURL:"https://cdn.intechopen.com/books/images_new/4584.jpg",editedByType:"Edited by",editors:[{id:"63299",title:"Prof.",name:"Francisco R.",middleName:null,surname:"Breijo-Marquez",slug:"francisco-r.-breijo-marquez",fullName:"Francisco R. Breijo-Marquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3528",title:"Cardiac Surgery",subtitle:"A Commitment to Science, Technology and Creativity",isOpenForSubmission:!1,hash:"95973b4f0e34524407c79ddb123a0d09",slug:"cardiac-surgery-a-commitment-to-science-technology-and-creativity",bookSignature:"Miguel Angel Maluf and Paulo Roberto Barbosa Evora",coverURL:"https://cdn.intechopen.com/books/images_new/3528.jpg",editedByType:"Edited by",editors:[{id:"106872",title:"Prof.",name:"Miguel",middleName:"Angel",surname:"Maluf",slug:"miguel-maluf",fullName:"Miguel Maluf"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3815",title:"Cardiac Arrhythmias",subtitle:"Mechanisms, Pathophysiology, and Treatment",isOpenForSubmission:!1,hash:"fe6dad804d0257a3922593b7861a1b74",slug:"cardiac-arrhythmias-mechanisms-pathophysiology-and-treatment",bookSignature:"Wilbert S. Aronow",coverURL:"https://cdn.intechopen.com/books/images_new/3815.jpg",editedByType:"Edited by",editors:[{id:"164597",title:"Dr.",name:"Wilbert S.",middleName:null,surname:"Aronow",slug:"wilbert-s.-aronow",fullName:"Wilbert S. Aronow"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3259",title:"Pulmonary Hypertension",subtitle:null,isOpenForSubmission:!1,hash:"30532bf64aeb50b027e54b102bfeae6c",slug:"pulmonary-hypertension",bookSignature:"Jean M. Elwing and Ralph J. Panos",coverURL:"https://cdn.intechopen.com/books/images_new/3259.jpg",editedByType:"Edited by",editors:[{id:"165463",title:"Dr.",name:"Jean",middleName:null,surname:"Elwing",slug:"jean-elwing",fullName:"Jean Elwing"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3289",title:"Cardiac Defibrillation",subtitle:null,isOpenForSubmission:!1,hash:"37b5f2758b30dc35fb41750fa68d2725",slug:"cardiac-defibrillation",bookSignature:"Damir Erkapic, Tamas Bauernfeind",coverURL:"https://cdn.intechopen.com/books/images_new/3289.jpg",editedByType:"Edited by",editors:[{id:"156236",title:"Dr.",name:"Damir",middleName:null,surname:"Erkapic",slug:"damir-erkapic",fullName:"Damir Erkapic"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"997",title:"Tachycardia",subtitle:null,isOpenForSubmission:!1,hash:"1a5908b405f4ffb028f51f29863469d0",slug:"tachycardia",bookSignature:"Takumi Yamada",coverURL:"https://cdn.intechopen.com/books/images_new/997.jpg",editedByType:"Edited by",editors:[{id:"68148",title:"Prof.",name:"Takumi",middleName:null,surname:"Yamada",slug:"takumi-yamada",fullName:"Takumi Yamada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:9,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"34340",doi:"10.5772/25763",title:"Heart Rate Variability: An Index of the Brain-Heart Interaction",slug:"heart-rate-variability-an-index-of-the-brain-heart-interaction",totalDownloads:5902,totalCrossrefCites:7,totalDimensionsCites:15,abstract:null,book:{id:"997",slug:"tachycardia",title:"Tachycardia",fullTitle:"Tachycardia"},signatures:"Ingrid Tonhajzerova, Igor Ondrejka, Zuzana Turianikova, Kamil Javorka, Andrea Calkovska and Michal Javorka",authors:[{id:"64469",title:"Dr.",name:"Ingrid",middleName:null,surname:"Tonhajzerova",slug:"ingrid-tonhajzerova",fullName:"Ingrid Tonhajzerova"},{id:"118980",title:"Dr.",name:"Igor",middleName:null,surname:"Ondrejka",slug:"igor-ondrejka",fullName:"Igor Ondrejka"},{id:"118981",title:"Mrs.",name:"Zuzana",middleName:null,surname:"Turianikova, Ing",slug:"zuzana-turianikova-ing",fullName:"Zuzana Turianikova, Ing"},{id:"118983",title:"Prof.",name:"Kamil",middleName:null,surname:"Javorka",slug:"kamil-javorka",fullName:"Kamil Javorka"},{id:"118984",title:"Prof.",name:"Andrea",middleName:null,surname:"Calkovska",slug:"andrea-calkovska",fullName:"Andrea Calkovska"},{id:"118985",title:"Dr.",name:"Michal",middleName:null,surname:"Javorka",slug:"michal-javorka",fullName:"Michal Javorka"}]},{id:"51405",doi:"10.5772/63456",title:"Myocardial Connexin-43 is Implicated in the Prevention of Malignant Arrhythmia in Rats Suffering from Essential Hypertension",slug:"myocardial-connexin-43-is-implicated-in-the-prevention-of-malignant-arrhythmia-in-rats-suffering-fro",totalDownloads:1541,totalCrossrefCites:6,totalDimensionsCites:6,abstract:"Gap-junction connexin (Cx) channels are important determinants of myocardial conduction and synchronization that is crucial for heart function. Hypertension-induced structural remodeling is associated with an increased risk of life-threatening arrhythmias and heart failure in both humans and experimental animals. Recent studies suggest that abnormal distribution and/or downregulation of Cx43 accompanied with altered protein kinase C (PKC)ε signaling in spontaneously hypertensive rats were linked with increased propensity to ventricular fibrillation compared to normotensive rats. By contrast, the long-term treatment of hypertensive rats with cardioprotective compounds such as melatonin, omega-3 fatty acids, or red palm oil resulted in protection from lethal arrhythmia. Their antiarrhythmic effect was attributed to the attenuation of abnormal Cx43 topology and modulation of Cx43 mRNA as well as protein expression and its functional phosphorylated forms. The latter might be attributed to upregulation of PKCε. It appears that maladaptive consequences of hypertension resulting in abnormal myocardial distribution of Cx43 and its downregulation can contribute to arrhythmogenesis and occurrence of malignant arrhythmias. On the other hand, the attenuation of myocardial Cx43 abnormalities by treatment with melatonin, omega-3 fatty acids, or red palm oil confers arrhythmia protection in rodent model of essential hypertension. Findings uncover novel mechanisms of cardioprotective effects of melatonin, omega-3 fatty acids, and red palm oil. Well-designed clinical trials are needed to explore antiarrhythmic potential of these compounds in human essential hypertension.",book:{id:"5216",slug:"update-on-essential-hypertension",title:"Update on Essential Hypertension",fullTitle:"Update on Essential Hypertension"},signatures:"Tamara Egan Benova, Barbara Szeiffova Bacova, Csilla Viczenczova,\nMiroslav Barancik and Narcis Tribulova",authors:[{id:"181938",title:"D.Sc.",name:"Narcisa",middleName:null,surname:"Tribulova",slug:"narcisa-tribulova",fullName:"Narcisa Tribulova"},{id:"185905",title:"Dr.",name:"Tamara",middleName:null,surname:"Egan Benova",slug:"tamara-egan-benova",fullName:"Tamara Egan Benova"},{id:"185907",title:"Dr.",name:"Barbara",middleName:null,surname:"Szeiffova Bacova",slug:"barbara-szeiffova-bacova",fullName:"Barbara Szeiffova Bacova"},{id:"185908",title:"Dr.",name:"Csilla",middleName:null,surname:"Viczenczova",slug:"csilla-viczenczova",fullName:"Csilla Viczenczova"}]},{id:"48384",doi:"10.5772/60418",title:"A Review on Amiodarone as an Antiarrhythmic Drug",slug:"a-review-on-amiodarone-as-an-antiarrhythmic-drug",totalDownloads:2774,totalCrossrefCites:4,totalDimensionsCites:6,abstract:"Antiarrhythmic drugs are used to suppress abnormal heart rhythms by different mechanisms. Amiodarone as an iodinated benzofuran derivative is a potent antiarrhythmic drug that is being used for the treatment of a wide variety of cardiac arrhythmias. Amiodarone has been reported to cause frequent and potentially serious toxicity. It was estimated that the prevalence of side effects was 15 % in the first year and increased to 50% with long-term therapy. Thyroid, lung, liver, ophthalmologic and neurologic systems can be affected by Amiodarone. Most of the adverse effects of the drug are related to its dosage and duration of administration. Therefore the effectiveness of Amiodarone in long-term treatment of patients with heart arrhythmia is limited because of the development of its adverse side effects.",book:{id:"4584",slug:"abnormal-heart-rhythms",title:"Abnormal Heart Rhythms",fullTitle:"Abnormal Heart Rhythms"},signatures:"Fereshteh Mehraein",authors:[{id:"173324",title:"Associate Prof.",name:"Fereshteh",middleName:null,surname:"Mehraein",slug:"fereshteh-mehraein",fullName:"Fereshteh Mehraein"}]},{id:"34335",doi:"10.5772/25800",title:"Ryanodine Receptor Channelopathies: The New Kid in the Arrhythmia Neighborhood",slug:"ryanodine-receptor-channelopathies-the-new-kid-in-the-arrhythmia-neighborhood",totalDownloads:2259,totalCrossrefCites:4,totalDimensionsCites:6,abstract:null,book:{id:"997",slug:"tachycardia",title:"Tachycardia",fullTitle:"Tachycardia"},signatures:"María Fernández-Velasco, Ana María Gómez, Jean-Pierre Benitah and Patricia Neco",authors:[{id:"64594",title:"Dr.",name:"Ana",middleName:null,surname:"Gomez",slug:"ana-gomez",fullName:"Ana Gomez"},{id:"71604",title:"Dr.",name:"Maria",middleName:null,surname:"Fernandez-Velasco",slug:"maria-fernandez-velasco",fullName:"Maria Fernandez-Velasco"},{id:"71606",title:"Dr.",name:"Jean-Pierre",middleName:null,surname:"Benitah",slug:"jean-pierre-benitah",fullName:"Jean-Pierre Benitah"},{id:"71607",title:"Dr.",name:"Patricia",middleName:null,surname:"Neco",slug:"patricia-neco",fullName:"Patricia Neco"}]},{id:"41776",doi:"10.5772/52512",title:"Principles of External Defibrillators",slug:"principles-of-external-defibrillators",totalDownloads:3718,totalCrossrefCites:2,totalDimensionsCites:5,abstract:null,book:{id:"3289",slug:"cardiac-defibrillation",title:"Cardiac Defibrillation",fullTitle:"Cardiac Defibrillation"},signatures:"Hugo Delgado, Jorge Toquero, Cristina Mitroi, Victor Castro and Ignacio Fernández Lozano",authors:[{id:"38793",title:"Dr.",name:"Jorge",middleName:null,surname:"Toquero",slug:"jorge-toquero",fullName:"Jorge Toquero"}]}],mostDownloadedChaptersLast30Days:[{id:"41776",title:"Principles of External Defibrillators",slug:"principles-of-external-defibrillators",totalDownloads:3710,totalCrossrefCites:2,totalDimensionsCites:5,abstract:null,book:{id:"3289",slug:"cardiac-defibrillation",title:"Cardiac Defibrillation",fullTitle:"Cardiac Defibrillation"},signatures:"Hugo Delgado, Jorge Toquero, Cristina Mitroi, Victor Castro and Ignacio Fernández Lozano",authors:[{id:"38793",title:"Dr.",name:"Jorge",middleName:null,surname:"Toquero",slug:"jorge-toquero",fullName:"Jorge Toquero"}]},{id:"46160",title:"Basic Mechanisms of Cardiac Arrhythmias",slug:"basic-mechanisms-of-cardiac-arrhythmias",totalDownloads:4464,totalCrossrefCites:1,totalDimensionsCites:1,abstract:null,book:{id:"3815",slug:"cardiac-arrhythmias-mechanisms-pathophysiology-and-treatment",title:"Cardiac Arrhythmias",fullTitle:"Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment"},signatures:"Andrey Moskalenko",authors:[{id:"63235",title:"Dr.",name:"Andrey",middleName:"V.",surname:"Moskalenko",slug:"andrey-moskalenko",fullName:"Andrey Moskalenko"}]},{id:"48384",title:"A Review on Amiodarone as an Antiarrhythmic Drug",slug:"a-review-on-amiodarone-as-an-antiarrhythmic-drug",totalDownloads:2769,totalCrossrefCites:4,totalDimensionsCites:5,abstract:"Antiarrhythmic drugs are used to suppress abnormal heart rhythms by different mechanisms. Amiodarone as an iodinated benzofuran derivative is a potent antiarrhythmic drug that is being used for the treatment of a wide variety of cardiac arrhythmias. Amiodarone has been reported to cause frequent and potentially serious toxicity. It was estimated that the prevalence of side effects was 15 % in the first year and increased to 50% with long-term therapy. Thyroid, lung, liver, ophthalmologic and neurologic systems can be affected by Amiodarone. Most of the adverse effects of the drug are related to its dosage and duration of administration. Therefore the effectiveness of Amiodarone in long-term treatment of patients with heart arrhythmia is limited because of the development of its adverse side effects.",book:{id:"4584",slug:"abnormal-heart-rhythms",title:"Abnormal Heart Rhythms",fullTitle:"Abnormal Heart Rhythms"},signatures:"Fereshteh Mehraein",authors:[{id:"173324",title:"Associate Prof.",name:"Fereshteh",middleName:null,surname:"Mehraein",slug:"fereshteh-mehraein",fullName:"Fereshteh Mehraein"}]},{id:"61466",title:"Idiopathic Ventricular Arrhythmias",slug:"idiopathic-ventricular-arrhythmias",totalDownloads:1529,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Idiopathic ventricular arrhythmias (VAs) occur with a mechanism that is unrelated to myocardial scar. Idiopathic VAs most commonly occur in patients without structural heart disease, but can occur in those with structural heart disease. Idiopathic VAs present as a sustained or a non-sustained ventricular tachycardia or premature ventricular contractions. Imaging examinations such as echocardiography, nuclear tests, and cardiac magnetic resonance imaging are helpful for excluding any association of an idiopathic VA occurrence with myocardial scar. For the past two decades, the sites of idiopathic VA origins, commonly endocardial but sometimes epicardial, have been increasingly recognized. Idiopathic VAs usually originate from specific anatomical structures and exhibit characteristic electrocardiograms based on their anatomical background. Idiopathic VAs are basically benign, but they require medical treatment or catheter ablation when idiopathic VAs are symptomatic, frequent, or cause tachycardia-induced cardiomyopathy. This book chapter describes the up-to-date information on the prevalence of idiopathic VA origins relevant to the anatomy, diagnosis, and treatment of idiopathic VAs.",book:{id:"6536",slug:"cardiac-arrhythmias",title:"Cardiac Arrhythmias",fullTitle:"Cardiac Arrhythmias"},signatures:"Takumi Yamada",authors:[{id:"68148",title:"Prof.",name:"Takumi",middleName:null,surname:"Yamada",slug:"takumi-yamada",fullName:"Takumi Yamada"}]},{id:"59994",title:"Atrial Flutter: Diagnosis and Management strategies",slug:"atrial-flutter-diagnosis-and-management-strategies",totalDownloads:1501,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Atrial flutter (AFL) is a regular, macro reentrant arrhythmia traditionally defined as a supraventricular tachycardia with an atrial rate of 240–320 beats per minute (bpm). Pathophysiology of atrial flutter and atrial fibrillation (AF) is closely related to the similar risk of stroke and they coexist clinically. Atrial flutter is classified to cavotricuspid isthmus (CTI) dependent (or typical) and non-isthmus dependent (atypical). Isthmus is a distinct structure in the right atrium (RA) through which atrial flutter passes and makes a good target for ablation therapy. Ablation is the primary therapy in atrial flutter, particularly in CTI dependent group, with regard to its safety profile and high success rate of approximately 90%. Three-dimensional electroanatomic mapping is progressively being used to ablate atypical forms of atrial flutter.",book:{id:"6536",slug:"cardiac-arrhythmias",title:"Cardiac Arrhythmias",fullTitle:"Cardiac Arrhythmias"},signatures:"Hamid Reza Bonakdar",authors:[{id:"227955",title:"Dr.",name:"Hamid Reza",middleName:null,surname:"Bonakdar",slug:"hamid-reza-bonakdar",fullName:"Hamid Reza Bonakdar"}]}],onlineFirstChaptersFilter:{topicId:"986",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:124,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}},{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}}]},series:{item:{id:"24",title:"Sustainable Development",doi:"10.5772/intechopen.100361",issn:"2753-6580",scope:"